

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Vancomycin-resistant enterococcus infection in... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-3/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-3" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention" />
    
            <meta name="og:title" content="F1000Research Article: Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.">
            <meta name="og:description" content="Read the latest article version by Esther Benamu, Stanley Deresinski, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12785">
            <meta name="article-id" content="11831">
            <meta name="dc.title" content="Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention">
            <meta name="dc.description" content="Vancomycin-resistant enterococcus (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach.">
            <meta name="dc.subject" content="Vancomycin resistant enterococcus, Hematopoietic stem cell transplantation, bacteremia">
            <meta name="dc.creator" content="Benamu, Esther">
            <meta name="dc.creator" content="Deresinski, Stanley">
            <meta name="dc.date" content="2018/01/02">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11831.1">
            <meta name="dc.source" content="F1000Research 2018 7:3">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Vancomycin resistant enterococcus">
            <meta name="prism.keyword" content="Hematopoietic stem cell transplantation">
            <meta name="prism.keyword" content="bacteremia">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/01/02">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="3">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11831.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-3">
            <meta name="citation_title" content="Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention">
            <meta name="citation_abstract" content="Vancomycin-resistant enterococcus (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach.">
            <meta name="citation_description" content="Vancomycin-resistant enterococcus (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach.">
            <meta name="citation_keywords" content="Vancomycin resistant enterococcus, Hematopoietic stem cell transplantation, bacteremia">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Esther Benamu">
            <meta name="citation_author_institution" content="Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, USA">
            <meta name="citation_author" content="Stanley Deresinski">
            <meta name="citation_author_institution" content="Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, USA">
            <meta name="citation_publication_date" content="2018/01/02">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="3">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11831.1">
            <meta name="citation_firstpage" content="3">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-3/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-3.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12785 /> <input type=hidden id=articleId name=articleId value=11831 /> <input type=hidden id=xmlUrl value="/articles/7-3/v1/xml"/> <input type=hidden id=xmlFileName value="-7-3-v1.xml"> <input type=hidden id=article_uuid value=c195b19b-48a5-45e3-a687-89d291b6b2fd /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11831.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11831.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-3"
  },
  "headline": "Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview...",
  "datePublished": "2018-01-02T13:51:26",
  "dateModified": "2018-01-02T13:51:26",
  "author": [
    {
      "@type": "Person",
      "name": "Esther Benamu"
    },    {
      "@type": "Person",
      "name": "Stanley Deresinski"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Vancomycin-resistant enterococcus (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-3.html",
            "name": "Vancomycin-resistant enterococcus infection in the hematopoietic stem..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Vancomycin-resistant enterococcus infection in the hematopoietic stem... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12785 data-id=11831 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11831.1" data-recommended="" data-doi="10.12688/f1000research.11831.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-3/v1/pdf?article_uuid=c195b19b-48a5-45e3-a687-89d291b6b2fd" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11831-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11831-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11831-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Benamu E and Deresinski S. Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):3 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11831.1" target=_blank>https://doi.org/10.12688/f1000research.11831.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11831-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11831 id=track-article-signin-11831 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11831?target=/articles/7-3.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12785 /> <input name=articleId type=hidden value=11831 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:esther.benamu@ucdenver.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Esther Benamu</span></a><sup>1</sup>,&nbsp;</span><span class="">Stanley Deresinski<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:esther.benamu@ucdenver.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Esther Benamu</span></a><sup>1</sup>,&nbsp;</span><span class="">Stanley Deresinski<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 02 Jan 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11831.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, USA<br/> <sup>2</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, USA<br/> <p> <div class=margin-bottom> Esther Benamu <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stanley Deresinski <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29179-29179></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29178-29177></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29177-29178></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Vancomycin-resistant <i>enterococcus</i> (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Vancomycin resistant enterococcus, Hematopoietic stem cell transplantation, bacteremia </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Esther Benamu (<a href="mailto:esther.benamu@ucdenver.edu">esther.benamu@ucdenver.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Esther Benamu </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Benamu E and Deresinski S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Benamu E and Deresinski S. Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):3 (<a href="https://doi.org/10.12688/f1000research.11831.1" target=_blank>https://doi.org/10.12688/f1000research.11831.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 02 Jan 2018, <b>7</b>(F1000 Faculty Rev):3 (<a href="https://doi.org/10.12688/f1000research.11831.1" target=_blank>https://doi.org/10.12688/f1000research.11831.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 02 Jan 2018, <b>7</b>(F1000 Faculty Rev):3 (<a href="https://doi.org/10.12688/f1000research.11831.1" target=_blank>https://doi.org/10.12688/f1000research.11831.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e165>Introduction</h2><p class="" id=d21151e168>Resistance to vancomycin in <i>enterococci</i> was first identified in isolates recovered in 1986, three decades after the introduction of this glycopeptide antibiotic<sup><a href="#ref-1">1</a></sup>. Since then, there has been a progressive, albeit geographically heterogeneous, increase in the prevalence of resistance, with among the highest rates in the world seen in the US, where vancomycin-resistant <i>enterococci</i> (VRE) is now one of the leading causes of nosocomial infections. VRE represent approximately one-third of <i>Enterococcus</i> isolates<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>, causing an estimated 1,300 deaths each year<sup><a href="#ref-4">4</a></sup>. Gastrointestinal (GI) colonization is frequent, and VRE bacteremia (VREB) has become a clinically significant complication in patients undergoing hematopoietic stem cell transplantation (HSCT). Chemotherapy-induced mucositis, neutropenia, prolonged and repeated hospitalizations, antibiotic exposure for therapeutic and prophylactic purposes (particularly with prophylactic antimicrobials with limited activity against Gram-positive [GP] organisms), and the widespread use of central venous catheters are some of the factors that place HSCT recipients at risk for VRE colonization and infection. In the last decade, numerous changes have occurred in the prevention and management of VRE infection, including the development of screening strategies together with attempts at decolonization and the advent of new antibiotics with activity against this organism. At the same time, the introduction of cord blood grafts and non-myeloablative conditioning regimens has resulted in an expansion of the pool of HSCT candidates, now also including older patients.</p><p class="" id=d21151e196>The emergence of VRE as a major cause of bacteremia in HSCT recipients has raised important clinical questions regarding the optimal means of prevention, the role of VRE colonization in predicting bacteremia, treatment, and the impact on HSCT outcomes.</p><p class="" id=d21151e199>We review the published literature addressing these aspects and summarize the latest advances in the prevention and treatment of invasive VRE infection in the HSCT recipient.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e204>Vancomycin-resistant enterococci colonization and infection in hematopoietic stem cell transplant recipients</h2><div class=section><a name=d21151e207 class=n-a></a><h3 class=section-title>Incidence, mortality, and common presentations of vancomycin-resistant enterococci infection</h3><p class="" id=d21151e211>Reported rates of VREB in HSCT recipients have ranged from 1.4–25%<sup><a href="#ref-5">5</a>–<a href="#ref-11">11</a></sup>, with more recent studies reporting prevalence rates of 10–15% (<a href="#T1">Table 1</a>). VRE has become the leading cause of bloodstream infection (BSI) among allogeneic HSCT recipients, especially in the early post-transplant period<sup><a href="#ref-7">7</a>,<a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. At the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, VRE was the most frequent cause of bacteremia in the first 35 days post-transplant by a threefold margin during the period of 2004–2006 and represented 53% of early BSIs in 2008–2009<sup><a href="#ref-7">7</a>,<a href="#ref-12">12</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Vancomycin-resistant enterococci in hematopoietic stem cell transplant recipients: colonization, bacteremia, risk factors, and outcomes.</h3><p id=d21151e251>ALL, acute lymphocytic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplant; AML, acute myeloid leukemia; auto-HSCT, autologous hematopoietic stem cell transplant; BJH, Barnes Jewish Hospital; BSI, bloodstream infection; Cdiff, <i>Clostridium difficile</i>; CML, chronic myeloid leukemia; CMV, cytomegalovirus; Colo, colonization; CS, comorbidity score; GC, glucocorticoid; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; HR, hazard ratio; IS, immunosuppression; LOS, length of hospital stay; MAR, myeloablative regimen; MDACC, Monroe Dunaway Anderson Cancer Center; MDS, myelodysplastic syndrome; Mort (Colo), mortality in colonized patients; Mort (Colo to BSI), mortality in patients progressing from colonization to bloodstream infection; Mort (non-Colo), mortality in non-colonized patients; MSKCC, Memorial Sloan Kettering Cancer Center; OR, odds ratio; PBSC, peripheral blood stem cell; PCR, polymerase chain reaction; RF, risk factor; RR, relative risk; TBI, total body irradiation; UCB, umbilical cord blood; UConn, University of Connecticut Health Center; URD, unrelated donor; VRE, vancomycin-resistant enterococci; VSE, vancomycin sensitive enterococci.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21151e258 class=n-a></a><thead><a name=d21151e260 class=n-a></a><tr><a name=d21151e262 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e264 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e267 class=n-a></a>Sample size,<br class=br>type of HSCT,<br class=br>years of<br class=br>study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e276 class=n-a></a>Prophylactic<br class=br>antibiotics?</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e281 class=n-a></a>VRE<br class=br>Screening</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e286 class=n-a></a>Colonization<br class=br>rate</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e292 class=n-a></a>Risk factors</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e295 class=n-a></a>VRE BSI<br class=br>incidence</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e300 class=n-a></a>Progression<br class=br>to VRE BSI</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e305 class=n-a></a>Risk factors for<br class=br>VRE BSI</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21151e310 class=n-a></a>VRE BSI outcomes:<br class=br>mortality (Mort),<br class=br>attributable mortality<br class=br>(Att Mort), and<br class=br>overall survival (OS)</th></tr></thead><tbody><a name=d21151e323 class=n-a></a><tr><a name=d21151e325 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e327 class=n-a></a>Kapur <i>et al</i>.<sup><a href="#ref-16">16</a></sup><br class=br>2000<br class=br>UConn</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e340 class=n-a></a>321<br class=br>Auto-HSCT<br class=br>1993–1998</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e347 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e350 class=n-a></a>Rectal swab<br class=br>or stool culture<br class=br>weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e357 class=n-a></a>50% (15/29)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e361 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e364 class=n-a></a>3%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e367 class=n-a></a>27%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e370 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e373 class=n-a></a>Mort: 70%<br class=br>Att Mort: 10%</td></tr><tr><a name=d21151e379 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e381 class=n-a></a>Almyroudis <i>et al</i>.<sup><a href="#ref-11">11</a></sup><br class=br>2005<br class=br>MSKCC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e394 class=n-a></a>298<br class=br>(adult and<br class=br>children)<br class=br>HSCT<br class=br>1999–2003</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e405 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e408 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e411 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e415 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e418 class=n-a></a>Pre-engraftment:<br class=br>22% (25.7%<br class=br>in adults)<br class=br><br class=br>Post-engraftment:<br class=br>19.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e430 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e433 class=n-a></a>Pre-engraftment:<br class=br>CML (OR=4.13,<br class=br><i>P</i> = 0.001)<br class=br>PBSCs (OR=1.8,<br class=br><i>P</i> = 0.04)<br class=br><br class=br>Post-engraftment:<br class=br>GVHD 2–4<br class=br>(OR 4.8, <i>P</i> &lt;0.0001),<br class=br>neutropenia (OR 3.4,<br class=br><i>P</i> = 0.002),<br class=br>GCs (OR 3.2,<br class=br><i>P</i> &lt;0.0001),<br class=br>kidney failure (OR<br class=br>3.8, <i>P</i> = 0.003),<br class=br>liver failure (OR 3.8,<br class=br><i>P</i> &lt;0.0001)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e486 class=n-a></a>Pre-engraftment:<br class=br>Mort: 20.3%<br class=br>Att Mort: 14%<br class=br>OS in BSI versus no<br class=br>BSI (46.8% versus<br class=br>64.1%, <i>P</i> &lt;0.01)<br class=br><br class=br>Post-engraftment:<br class=br>Mort: 17.2%<br class=br>Att Mort: 0<br class=br>OS BSI versus no BSI<br class=br>(55% versus 63.3%,<br class=br><i>P</i> = 0.25)</td></tr><tr><a name=d21151e520 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e522 class=n-a></a>Avery <i>et al</i>.<sup><a href="#ref-15">15</a></sup><a href="#fn1">*</a><br class=br>2005<br class=br>Cleveland<br class=br>Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e539 class=n-a></a>281<br class=br>Allo-HSCT<br class=br>1997–2003</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e546 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e549 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e552 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e556 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e559 class=n-a></a>4.3%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e562 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e564 class=n-a></a>URD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e567 class=n-a></a>Mort: 100%<br class=br>Att Mort: 10%</td></tr><tr><a name=d21151e573 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e575 class=n-a></a>Matar <i>et al</i>.<sup><a href="#ref-5">5</a></sup><br class=br>2006<br class=br>MDACC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e588 class=n-a></a>653<br class=br>HSCT<br class=br>2001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e595 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e597 class=n-a></a>Stool culture<br class=br>weekly x3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e602 class=n-a></a>4.7%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e606 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e609 class=n-a></a>1.4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e612 class=n-a></a>28% (9/32)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e615 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e618 class=n-a></a>Att Mort: 7%</td></tr><tr><a name=d21151e622 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e624 class=n-a></a>Dubberke <i>et al</i>.<sup><a href="#ref-23">23</a></sup> <a href="#fn1">*</a><br class=br>2006<br class=br>BJH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e640 class=n-a></a>968 auto-<br class=br>HSCT; 612<br class=br>allo-HSCT<br class=br>1996–2002</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e649 class=n-a></a>No<a href="#fn1">*</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e654 class=n-a></a>Stool culture in<br class=br>patients tested<br class=br>for Cdiff</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e661 class=n-a></a>21%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e665 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e668 class=n-a></a>3.9%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e671 class=n-a></a>13% (42/334)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e674 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e677 class=n-a></a>Mort: 53%<br class=br>Att Mort: 12.5%</td></tr><tr><a name=d21151e684 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e686 class=n-a></a>Zirakzadeh <i>et al</i>.<sup><a href="#ref-17">17</a></sup><br class=br>2008<br class=br>Mayo Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e699 class=n-a></a>217 allo-HSCT<br class=br>1998–2004</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e704 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e707 class=n-a></a>pre-HSCT<br class=br>swab or stool<br class=br>culture or PCR<br class=br>twice weekly<br class=br>and with<br class=br>diarrhea</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e720 class=n-a></a>10%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e724 class=n-a></a>Cdiff, renal<br class=br>failure, AML,<br class=br>low platelet<br class=br>count, TBI,<br class=br>MAR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e735 class=n-a></a> 2.8%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e738 class=n-a></a>27% (6/22)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e741 class=n-a></a>Colo (27% versus<br class=br>0%, <i>P</i>≤0.01)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e749 class=n-a></a>Mort: 27.6%<br class=br>Mort (Colo): 45%<br class=br>Mort (non-Colo): 25%<br class=br>(HR 2.1, <i>P</i> = 0.028)<br class=br>Mort (Colo to BSI):<br class=br>83%</td></tr><tr><a name=d21151e767 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e769 class=n-a></a>Weinstock <i>et al</i>.<sup><a href="#ref-12">12</a></sup><br class=br>2007<br class=br>MSKCC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e782 class=n-a></a>92 allo-HSCT<br class=br>2004–2006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e787 class=n-a></a>Yes<a href="#fn1">*</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e792 class=n-a></a>Stool culture on<br class=br>admission for<br class=br>HSCT and also<br class=br>with diarrhea</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e801 class=n-a></a>40%<br class=br>Pre-HSCT<br class=br>n = 2, at<br class=br>HSCT n = 25,<br class=br>and post-<br class=br>HSCT n = 10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e815 class=n-a></a>Acute<br class=br>leukemia,<br class=br>refractory<br class=br>anemia<br class=br>with excess<br class=br>blasts</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e828 class=n-a></a>15% (14/92)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e831 class=n-a></a>4% (13/37)<br class=br><br class=br>27% (10/37)<br class=br>pre-HSCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e839 class=n-a></a>Colo (34% versus<br class=br>1.8%, <i>P</i> &lt;0.01)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e847 class=n-a></a>Mort: 50%<br class=br>Att Mort: 14.3%<br class=br><br class=br>Mort for VRE BSI<br class=br>versus other BSI (HR<br class=br>5.1, <i>P</i> = 0.5)<br class=br>Mort (non-Colo)<br class=br>versus Mort (Colo non-<br class=br>progressors)<br class=br>(HR 0.8, <i>P</i> = 0.55)</td></tr><tr><a name=d21151e875 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e877 class=n-a></a>Kamboj <i>et al</i>.<sup><a href="#ref-7">7</a></sup><br class=br>2010<br class=br>MSKCC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e890 class=n-a></a>247<br class=br>allo-HSCT<br class=br>2008–2009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e897 class=n-a></a>Yes<a href="#fn1">*</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e902 class=n-a></a>Rectal swab<br class=br>culture weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e907 class=n-a></a>27.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e911 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e913 class=n-a></a>11% 13/23<br class=br>(57%) were<br class=br>colonized</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e920 class=n-a></a>19% (13/68)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e923 class=n-a></a>pre-HSCT Colo<br class=br>(OR=3.88, <i>P</i> = 0.005)<br class=br><br class=br>T cell depletion<br class=br>(OR=10.89, <i>P</i> = 0.028)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e939 class=n-a></a>Mort in VRE BSI<br class=br>versus non-VRE BSI<br class=br>versus no BSI<br class=br>4.4% versus 15%<br class=br>versus 2%<br class=br><br class=br>Att Mort: 9%</td></tr><tr><a name=d21151e954 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e956 class=n-a></a>Vydra <i>et al</i>.<sup><a href="#ref-18">18</a></sup><br class=br>2012<br class=br>University of<br class=br>Minnesota</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e971 class=n-a></a>752<br class=br>HSCT 491<br class=br>adults<br class=br>2004–2008</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e980 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e983 class=n-a></a>Perirectal swab<br class=br>cultures weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e988 class=n-a></a>23%<br class=br><br class=br>6% (43/752)<br class=br>pre-HSCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e997 class=n-a></a>Leukemia<br class=br>MDS<br class=br>Age &gt;60</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1004 class=n-a></a>8%<a href="#fn2">**</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1009 class=n-a></a>14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1012 class=n-a></a>pre-HSCT Colo<br class=br>RR=3.3 (<i>P</i> = 0.01)<br class=br>post-HSCT Colo<br class=br>RR=7.7 (<i>P</i> &lt;0.01)<br class=br>Engraftment delay<br class=br>acute GVHD 3–4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1032 class=n-a></a>Mort<a href="#fn2">**</a>: 38%<br class=br><br class=br>OS VRE BSI versus<br class=br>VSE BSI: 23% versus<br class=br>48% (<i>P</i> = 0.04)</td></tr><tr><a name=d21151e1049 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1051 class=n-a></a>Kang <i>et al</i>.<sup><a href="#ref-10">10</a></sup><br class=br>2013<br class=br>University of<br class=br>Chicago</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1066 class=n-a></a>152<br class=br>HSCT<br class=br>2008–2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1073 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1076 class=n-a></a>Rectal swab<br class=br>weekly cultures</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1081 class=n-a></a>100%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1085 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1087 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1089 class=n-a></a>12.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1092 class=n-a></a>vancomycin<br class=br>(<i>P</i> = 0.017), prolonged<br class=br>neutropenia<br class=br>(<i>P</i> = 0.001), IS<br class=br>(<i>P</i> &lt;0.001),<br class=br>VRE at week 1<br class=br>(<i>P</i> = 0.05)<a href="#fn3">***</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1122 class=n-a></a>Non-progressors<br class=br>versus progressors<br class=br>Mort: 4% versus 29%<br class=br>(<i>P</i> = 0.001)</td></tr><tr><a name=d21151e1135 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1137 class=n-a></a>Tavadze <i>et al</i>.<sup><a href="#ref-6">6</a></sup><br class=br>2014<br class=br>Cleveland<br class=br>Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1152 class=n-a></a>800<br class=br>Allo-HSCT<br class=br>1997–2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1159 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1162 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1165 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1169 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1172 class=n-a></a>9.5%<br class=br>17%<br class=br>(n = 13) previous<br class=br>VRE or Colo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1181 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1183 class=n-a></a>Later year of HSCT<br class=br>(HR=1.06,<br class=br><i>P</i> = 0.037)<br class=br>High HSCT-CS<br class=br>(HR=2.02,<br class=br><i>P</i> = 0.022)<br class=br>ALL (HR=2.20,<br class=br><i>P</i> = 0.003)<br class=br>URD (HR=2.75,<br class=br><i>P</i> &lt;0.001)<br class=br>UCB donor (HR=3.11,<br class=br><i>P</i> = 0.003)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1220 class=n-a></a>Mort: 96%<br class=br><br class=br>Att Mort: 5%<br class=br><br class=br>Worse OS:<br class=br>VRE BSI (HR=4.45,<br class=br><i>p</i>&lt;0.001)<br class=br>Year of transplant<br class=br>Male gender<br class=br>Older age<br class=br>Prior chemotherapies<br class=br>High HSCT-CS<br class=br>Lack of remission at<br class=br>HSCT<br class=br>URD<br class=br>CMV-<br class=br>positive donor</td></tr><tr><a name=d21151e1259 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1261 class=n-a></a>Satlin <i>et al</i>.<sup><a href="#ref-13">13</a></sup><br class=br>2014<br class=br>Weill Cornell<br class=br>University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1276 class=n-a></a>238<br class=br>allo-HSCT<br class=br>287<br class=br>auto-SCT<br class=br>2007–2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1287 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1290 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1293 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1297 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1300 class=n-a></a>Allo-HSCT:<br class=br>16.4%<br class=br><br class=br>Auto-HSCT:<br class=br>3.8%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1310 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1313 class=n-a></a>Mismatched PBSCs<br class=br>(HR=3.76, <i>P</i> = 0.04)<br class=br><br class=br>Time to engraftment<br class=br>(HR=1.06 per day,<br class=br>95%, <i>P</i> = 0.005)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1332 class=n-a></a>Mort: 18%</td></tr><tr><a name=d21151e1336 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1338 class=n-a></a>Ford <i>et al</i>.<sup><a href="#ref-27">27</a></sup><br class=br>2015<br class=br>Salt Lake City</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1351 class=n-a></a>300 auto-HSCT<br class=br>2006–2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1356 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1359 class=n-a></a>Stool cultures<br class=br>on admission<br class=br>and weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1366 class=n-a></a>36%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1370 class=n-a></a>Lymphoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1373 class=n-a></a>3%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1376 class=n-a></a>8.3% (9/108)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1379 class=n-a></a>Colo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1382 class=n-a></a>Mort: 0</td></tr><tr><a name=d21151e1386 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1388 class=n-a></a>Ford <i>et al</i>.<sup><a href="#ref-8">8</a></sup><br class=br>2017<br class=br>Salt Lake City</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1401 class=n-a></a>161<br class=br>HSCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1406 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1409 class=n-a></a>Stool cultures<br class=br>on admission<br class=br>and weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1416 class=n-a></a>pre-HSCT:<br class=br>61% (66/109)<br class=br><br class=br>day of HSCT:<br class=br>43%<br class=br>(58/134)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1429 class=n-a></a>Time from<br class=br>leukemia to<br class=br>HSCT<br class=br><br class=br>Pre-HSCT<br class=br>Colo: RF of<br class=br>subsequent<br class=br>Colo<br class=br>(HR=3.8)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1448 class=n-a></a>12%<br class=br><br class=br>Pre-<br class=br>engraftment<br class=br>(10)<br class=br><br class=br>Post-<br class=br>engraftment<br class=br>(9)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1466 class=n-a></a>10% (at day 30)<br class=br><br class=br>12.5% (at day 90)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1472 class=n-a></a>Pre-engraftment:<br class=br>Pre-HSCT Colo<br class=br>Colo at admission<br class=br><br class=br>Post-engraftment:<br class=br>GVHD<br class=br>Pre-HSCT Colo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1486 class=n-a></a>Pre-engraftment Mort:<br class=br>20%<br class=br><br class=br>Similar OS in VRE BSI<br class=br>versus other BSI<br class=br><br class=br>Worse OS:<br class=br>All BSI (HR=3.6,<br class=br><i>P</i> &lt;0.006)<br class=br>Post-engraftment VRE<br class=br>BSI<br class=br>versus pre-<br class=br>engraftment VRE BSI<br class=br>(10% versus 80%,<br class=br><i>P</i> = 0.0007)<br class=br><br class=br>No influence of Colo<br class=br>on LOS or OS, trend<br class=br>to greater healthcare<br class=br>costs</td></tr><tr><a name=d21151e1532 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1534 class=n-a></a>Hefazi <i>et al</i>.<sup><a href="#ref-9">9</a></sup><br class=br>2016<br class=br>Mayo Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1547 class=n-a></a>203 AML<br class=br>Allo-HSCT<br class=br>2004–2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1554 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1557 class=n-a></a>Perirectal or<br class=br>stool PCR on<br class=br>day 0 and<br class=br>twice weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1566 class=n-a></a>Day 0: 36%<br class=br><br class=br>Day 1–100:<br class=br>10%<br class=br><br class=br>&gt;Day 100:<br class=br>8%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1580 class=n-a></a>HSCT-CS ≥3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1583 class=n-a></a>Day 0–30: 5%<br class=br>91% (10) were<br class=br>colonized<br class=br><br class=br>Day 30–100:<br class=br>0.4% (1)<br class=br><br class=br>&gt;Day 100: 4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1599 class=n-a></a>11% (10/88)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1602 class=n-a></a>Age ≥60 (<i>P</i> = 0.04)<br class=br>HSCT-CS ≥3<br class=br>(<i>P</i> = 0.03)<br class=br>Colo (<i>P</i> = 0.003)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e1621 class=n-a></a>Mort: 55% (6/11), 9%<br class=br>within 100 days<br class=br>Att Mort: 0<br class=br><br class=br>Pre-HSCT VRE<br class=br>Colo no impact on<br class=br>outcomes/OS<br class=br><br class=br>Colo after day 0<br class=br>associated with worse<br class=br>survival (HR=2.2,<br class=br><i>P</i> = 0.03)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21151e1652 class=n-a></a><p id=fn1> *Studies in which all individuals developing febrile neutropenia were automatically started on empirical vancomycin</p><p id=fn2>**Specific data observed in adults</p><p id=fn3>***Colonization, prior VRE, or delayed engraftment were not risk factors</p></div></div></div><p class="" id=d21151e1666>VRE have often been considered an organism of limited virulence<sup><a href="#ref-14">14</a></sup>. However, data suggest that VREB may be associated with severe presentations in HSCT recipients, with, in at least some reported experiences, high rates of septic shock<sup><a href="#ref-7">7</a>,<a href="#ref-13">13</a>,<a href="#ref-15">15</a></sup>. Mortality estimates have been widely variable, ranging from 4–100%<sup><a href="#ref-11">11</a>–<a href="#ref-13">13</a>,<a href="#ref-15">15</a>–<a href="#ref-18">18</a></sup>. The most common manifestation of VRE infection in HSCT recipients is bacteremia—often catheter associated—usually occurring in the early post-transplant and peri-engraftment period, in the setting of severe mucositis and bacterial translocation<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a>,<a href="#ref-12">12</a>,<a href="#ref-13">13</a>,<a href="#ref-15">15</a></sup>. Other presentations include infections of the urinary tract, soft tissue, intra-abdominal space, and biliary tract as well as endocarditis and, rarely, infections of the central nervous system<sup><a href="#ref-10">10</a>,<a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup>.</p></div><div class=section><a name=d21151e1722 class=n-a></a><h3 class=section-title>Vancomycin-resistant enterococci colonization and vancomycin-resistant enterococci bacteremia and their impact on hematopoietic stem cell transplant outcomes</h3><p class="" id=d21151e1726>Patients with hematologic malignancies, especially those who undergo HSCT, are at a particularly high risk for VRE colonization and subsequent infection<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a>,<a href="#ref-22">22</a></sup>. Areas of controversy in which there are conflicting data are the association between pre-HSCT VRE colonization and the risk of VREB<sup><a href="#ref-10">10</a>,<a href="#ref-12">12</a>,<a href="#ref-18">18</a></sup> as well as the effect VRE colonization and bacteremia have on HSCT-associated mortality<sup><a href="#ref-6">6</a>,<a href="#ref-15">15</a>,<a href="#ref-17">17</a>,<a href="#ref-23">23</a></sup>.</p><p class="" id=d21151e1762>The frequency and impact of the progression from colonization to bacteremia is still not well understood. Studies report varying rates of such progression in the early post-HSCT period that range from 10–34%<sup><a href="#ref-5">5</a>,<a href="#ref-7">7</a>–<a href="#ref-9">9</a>,<a href="#ref-12">12</a>,<a href="#ref-18">18</a></sup>, together with mortality rates that range from 40–100%<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a></sup>. This variability may result from differing severity of underlying illness in largely heterogeneous transplant populations as well as different screening and treatment strategies, changing epidemiology of VRE colonization across transplant centers, and evolving transplant practice and supportive care measures over the last two decades. In addition to these varied reported experiences, while some authors have reported that VRE colonization and/or BSI are independent risk factors for mortality<sup><a href="#ref-12">12</a>,<a href="#ref-18">18</a>,<a href="#ref-24">24</a></sup>, others have argued against causality and conclude that these are simply markers of a complicated post-transplant course<sup><a href="#ref-6">6</a>,<a href="#ref-23">23</a>,<a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>.</p><p class="" id=d21151e1811>Clarification of the relationship between VRE colonization and the risk of subsequent VREB in these patients is necessary to accurately inform decisions related to the use of empirical or pre-emptive VRE-active therapy in HSCT recipients.</p></div><div class=section><a name=d21151e1814 class=n-a></a><h3 class=section-title>Vancomycin-resistant enterococci colonization: prevalence and risk factors</h3><p class="" id=d21151e1818>The prevalence of VRE colonization in HSCT recipients has increased over time. In 2001, 4.7% of HSCT recipients at the M.D. Anderson Cancer Center were colonized<sup><a href="#ref-5">5</a></sup>. During the period of 1998–2004, VRE was present in 10% of individuals admitted for HSCT at the Mayo Clinic, Rochester<sup><a href="#ref-17">17</a></sup>. In the same center, the prevalence nearly quadrupled in the following decade<sup><a href="#ref-9">9</a></sup>. During the 10-year study period, all 203 allogeneic HSCT recipients were screened for fecal, perianal, or perirectal VRE colonization by PCR testing of colonial growth on blood agar plates at the time of admission for HSCT and with subsequent twice-weekly surveillance. VRE was detected prior to transplantation in 73 (36%) patients, while 21 (10%) were newly colonized in the first 100 days post-HSCT and 107 (53%) remained uncolonized. Those colonized at the time of admission for HSCT had a higher comorbidity index compared to non-colonized (<i>P</i> = 0.02) individuals. Comparison of the periods before and after the introduction of PCR screening in 2009 revealed no differences in rates of colonization and were in overall agreement with other contemporary studies that found a prevalence of 23–40%<sup><a href="#ref-7">7</a>,<a href="#ref-9">9</a>,<a href="#ref-12">12</a>,<a href="#ref-18">18</a></sup>.</p><p class="" id=d21151e1849>To analyze the relationship among VRE colonization, bacteremia, and post-transplant mortality, Ford and colleagues studied 161 patients with acute myeloid, leukemic, or biphenotypic leukemia who underwent HSCT between 2006 and 2014, making a distinction between colonization during the preparative period before HSCT and colonization detected immediately before HSCT<sup><a href="#ref-8">8</a></sup>. In their cohort, 109 patients had weekly surveillance stool cultures before admission for HSCT. A total of 66 (61%) were VRE positive in the pre-HSCT period, with the greatest risk factor being the number of inpatient days in the interval between the initial admission for leukemia and the HSCT. One-third of these patients were no longer colonized at the time of admission for HSCT (58 of 134, 43%) but were at increased risk for subsequent colonization. Among those apparently re-colonized, the newly acquired strain differed from the original one more than half the time.</p><p class="" id=d21151e1856>Fewer studies have examined VRE colonization and bacteremia in autologous HSCT recipients<sup><a href="#ref-16">16</a>,<a href="#ref-27">27</a></sup>. Ford and colleagues described their experience at the Intermountain Blood and Transplant Program, where 36% of 300 autologous HSCT recipients were colonized<sup><a href="#ref-27">27</a></sup>. Of these, 8.3% developed VREB, and all nine bacteremic patients were previously colonized. Neither VRE colonization nor bacteremia was associated with reduced overall survival (OS). A separate study conducted at Cornell<sup><a href="#ref-28">28</a></sup> of 326 HSCT recipients (197 allogeneic, 129 autologous) determined that, compared to autologous HSCT recipients, patients with allogeneic HSCT were more likely to be colonized on admission for HSCT (28% versus 12%, <i>P</i> &lt;0.001) and to become colonized during their transplant hospitalization (52% versus 20%, <i>P</i> &lt;0.001).</p><p class="" id=d21151e1880>The risk factors for VRE carriage in HSCT recipients are similar to those identified in cancer patients. Heavy antimicrobial exposure, severe underlying disease, and frequent and prolonged contact with the healthcare system are among the risks most commonly described in the literature<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-12">12</a>,<a href="#ref-17">17</a>,<a href="#ref-18">18</a>,<a href="#ref-29">29</a>–<a href="#ref-31">31</a></sup>. More than their simple presence, the density of <i>enterococci</i> in the GI tract plays a key role in VRE colonization and the susceptibility to VREB<sup><a href="#ref-14">14</a></sup>. <i>Enterococci</i> constitute a small proportion of the gut microbiota<sup><a href="#ref-32">32</a></sup>. Under exposure to antibiotics with broad-spectrum Gram-negative (GN) and GP bacteria coverage, shifts in the intestinal flora facilitate enterococcal dominance. When stimulated via Toll-like receptors by flagella and lipopolysaccharide of GN rods and anaerobes, Paneth cells in the GI tract produce REGIIIγ, a C-type lectin with antimicrobial activity against GP bacteria<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Depletion of GN rods under antibiotic pressure results in enterococcal overgrowth. Researchers at the MSKCC recently showed that the administration of metronidazole, neomycin, and vancomycin allowed VRE to become the predominant intestinal species in mice, remaining for up to two months after antibiotic discontinuation. In humans, VRE invasion of the bloodstream was preceded by its predominance in the GI tract<sup><a href="#ref-35">35</a></sup>. In a later study, enterococcal domination increased the risk of VRE BSI by ninefold<sup><a href="#ref-36">36</a></sup>. <i>Clostridium difficile</i> infection and its treatment with oral metronidazole or oral vancomycin<sup><a href="#ref-37">37</a></sup> have also been linked to the development of VRE colonization and infection. These two infections share epidemiological features and, mechanistically, may occur under antibiotic pressure, possibly through the inhibition of Paneth cell secretion of alpha-defensins, resulting in their co-occurrence as a frequent phenomenon<sup><a href="#ref-17">17</a>,<a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>.</p></div><div class=section><a name=d21151e1953 class=n-a></a><h3 class=section-title>Impact of hematopoietic stem cell transplant colonization on vancomycin-resistant enterococci bacteremia</h3><p class="" id=d21151e1957>VRE colonization before and after HSCT is associated with an increased risk of VRE infection<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a></sup> and has been found to be an independent risk factor for VREB in several studies<sup><a href="#ref-7">7</a>,<a href="#ref-9">9</a>,<a href="#ref-18">18</a></sup> (<a href="#T1">Table 1</a>).</p><p class="" id=d21151e1980>Ford and colleagues analyzed the impact of colonization detected at different time points pre-transplantation—during the period between leukemia diagnosis and HSCT and at the time of admission for HSCT—and post-HSCT on the incidence of pre- and post-engraftment bacteremia. Patients colonized before HSCT had an increased risk of HSCT-associated VRE infections (32% versus 7%, <i>P</i> = 0.001), including bacteremia during both pre-engraftment (9%) and post-engraftment (9%) periods, while none were observed in patients without prior colonization. Pre-engraftment bacteremia was also more common in the cohort of patients colonized at the time of admission (<i>P</i> = 0.03). In contrast, new onset of colonization at a later time was not a predictor of bacteremia.</p><p class="" id=d21151e1989>While the prevalence of colonization has increased in recent years, the frequency of progression to VREB in colonized patients appears to have decreased from 27–34% in early studies<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-10">10</a>,<a href="#ref-18">18</a></sup> to 10–15% according to more recent data<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a>,<a href="#ref-40">40</a></sup>.</p><p class="" id=d21151e2015>Identifying the risk factors that contribute to the development of subsequent VREB in colonized HSCT recipients might enable the prediction of patients who could benefit from early empirical anti-VRE antibiotic therapy in the case of suspected GP bacteremia.</p><p class="" id=d21151e2018>This specific question was addressed in a retrospective chart review of patients who received allogeneic HSCT from 2008 to 2011<sup><a href="#ref-10">10</a></sup>. VRE colonization was tested with weekly rectal swab cultures until confirmed to be positive. Neutropenic patients received antibacterial prophylaxis with moxifloxacin and, when febrile, received vancomycin intravenously according to guideline recommendations, although adherence was less than complete. Of 152 colonized patients, 19 (13%) patients subsequently developed VREB. Risk factors for progression to bacteremia included the use of vancomycin after VRE detection (<i>P</i> = 0.017), prolonged duration of neutropenia (&gt;30 days) (<i>P</i> = 0.001), immunosuppression (<i>P</i> &lt;0.001), and timing of first VRE surveillance screen positivity at week one from HSCT (<i>P</i> = 0.005). Interestingly, VRE colonization during a previous admission was not an independent risk factor for bacteremia (<i>P</i> = 1.0).</p><p class="" id=d21151e2042>A study conducted at the Mayo Clinic revealed that 10 (91%) of the 11 patients who developed VREB in the 30 days following HSCT were previously colonized as determined by PCR in stool or perirectal swab. Older age (&gt;60 years) (hazard ratio [HR] 5.1 [1.0–34], <i>P</i> = 0.04), high HSCT-associated comorbidity index (HR 4.6 [1.1–24], <i>P</i> = 0.03), and VRE colonization (HR 15 [2.7–299], <i>P</i> = 0.003) were independent risk factors for the development of VRE BSI<sup><a href="#ref-9">9</a></sup>. The overall rate of progression from colonization to bacteremia was 11%. In colonized patients with febrile neutropenia (FN), it was 21%. Moreover, in FN patients with GP bacteremia, VRE was eventually identified in 67% of cases in the VRE-colonized but in only 25% of the non-colonized patients. Thus, rapid identification of colonized patients with the highly sensitive PCR testing<sup><a href="#ref-41">41</a></sup> may prove useful in dictating appropriate initial antibiotic therapy in the febrile neutropenic HSCT recipient. Nevertheless, the use of PCR in the detection of VRE has diagnostic limitations<sup><a href="#ref-42">42</a>–<a href="#ref-44">44</a></sup>. The detection of <i>vanB</i> sequences carries a high false-positivity rate, owing to the presence of <i>vanB</i> genetic elements in intestinal non-enterococcal bacteria, notably in anaerobes such as <i>Clostridium</i> spp. and <i>Streptococcus</i> spp.<sup><a href="#ref-45">45</a></sup>. In a recent analysis of the performance of the GeneXpert® <i>vanA/vanB</i> assay (Cepheid AB, Solna, Sweden), PCR had a sensitivity of 87.1%, a specificity of 99.7%, and positive and negative predictive values of 98.0% and 97.7%, respectively. However, the <i>vanB</i> PCR had a considerably lower specificity of 77.6% and a PPV of 0.4<sup><a href="#ref-46">46</a></sup>. Therefore, in institutions in which <i>vanB</i> VRE is prevalent, the detection of VRE by PCR may require confirmatory testing by culture.</p></div><div class=section><a name=d21151e2100 class=n-a></a><h3 class=section-title>Other risk factors for vancomycin-resistant enterococci bacteremia</h3><p class="" id=d21151e2104>Individuals with hematological malignancies are frequently hospitalized, often for long periods of time, needing central venous access and often requiring ICU level of care, all factors that, in addition to immunosuppression and neutropenia, further increase their risk of VREB. Prolonged and repeated antibiotic exposures, in particular to ceftriaxone and metronidazole, have been associated with VRE colonization and infection in multiple patient populations, including HSCT recipients. Previous studies showed that vancomycin exposure increased the risk of developing VRE infection<sup><a href="#ref-47">47</a>–<a href="#ref-51">51</a></sup>. Taur and colleagues reported that shifts in the intestinal microbiota towards VRE domination and bacteremia were more likely to occur with the use of metronidazole compared with β-lactams or vancomycin<sup><a href="#ref-36">36</a>,<a href="#ref-52">52</a></sup>. In a study by Satlin <i>et al</i>., VRE did not cause any of 101 BSIs in neutropenic patients not receiving antibacterials but caused 32 (55%) of 58 BSIs in neutropenic patients receiving a broad-spectrum β-lactam agent, especially meropenem (<i>P</i> &lt;0.001)<sup><a href="#ref-13">13</a></sup>. The investigators concluded that the development of GP bacteremia in the setting of broad-spectrum antibiotic use warrants the addition of antibiotics active against VRE, whereas a first episode of FN with bacteremia in a patient not receiving antibiotics should not prompt empiric VRE coverage. In a later study, they suggested that the latter group could benefit from empirical VRE coverage if prior colonization is documented<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d21151e2136>Immunosuppression and disruption of the intestinal mucosa facilitate bacterial translocation in HSCT recipients<sup><a href="#ref-53">53</a></sup>. Prolonged neutropenia and mucositis in the peri-engraftment period and, occurring later, graft-versus-host disease (GVHD) predispose these patients to the development of VREB<sup><a href="#ref-8">8</a>,<a href="#ref-13">13</a>,<a href="#ref-18">18</a></sup>. Paneth cells have a key role controlling the inflammatory response to pathogens in the small bowel and maintaining its commensal flora. In GVHD, the loss of Paneth cells facilitates bacterial translocation<sup><a href="#ref-54">54</a>–<a href="#ref-56">56</a></sup>.</p><p class="" id=d21151e2160>In a 2012 study, the risk of developing VREB increased with each week’s delay in engraftment, rising from 4.5% before day 21 to 15% between day 36 and 42, and was highest for those not engrafted by day 42<sup><a href="#ref-18">18</a></sup>. Umbilical cord blood transplant recipients in whom engraftment is particularly delayed appear to be at higher risk<sup><a href="#ref-6">6</a></sup> of VREB.</p><p class="" id=d21151e2171>In a recent publication, Webb <i>et al</i>. proposed an integrative scoring system for the prediction of VREB in HSCT recipients<sup><a href="#ref-57">57</a></sup>. The risk factors in the model included VRE colonization with highest score weight, severe neutropenia, GI disruption, renal insufficiency, and the use of antibiotics (anti-anaerobic, carbapenem, aminoglycoside, and cephalosporin). A score greater or equal to five points would identify patients at high risk of VREB with 77% sensitivity and 79% specificity. More importantly, compared to using colonization status alone, the use of the scoring system would have resulted in a 43.2% reduction of anti-VRE antibiotic use.</p></div><div class=section><a name=d21151e2181 class=n-a></a><h3 class=section-title>Impact of vancomycin-resistant enterococci bacteremia on hematopoietic stem cell transplant outcomes</h3><p class="" id=d21151e2185>Early studies reported 100-day mortality rates as high as 83–100%<sup><a href="#ref-6">6</a>,<a href="#ref-12">12</a>,<a href="#ref-15">15</a>,<a href="#ref-17">17</a></sup> and attributable mortality rates of 8–14%<sup><a href="#ref-7">7</a>,<a href="#ref-11">11</a>,<a href="#ref-12">12</a>,<a href="#ref-15">15</a></sup> in HSCT recipients with VRE BSI (<a href="#T1">Table 1</a>).</p><p class="" id=d21151e2217>VREB occurring early post-HSCT, especially in the pre-engraftment period, has been associated with poor outcomes and, in some studies, is a risk factor for worsened survival<sup><a href="#ref-6">6</a>,<a href="#ref-11">11</a>,<a href="#ref-18">18</a></sup>. In their report of cases of early VREB, all occurring within 21 days of HSCT, Avery <i>et al</i>. observed that all 10 patients died within 73 days, despite appropriate therapy and likely source control (indwelling catheter). Only one death, however, was attributed to VRE infection in this cohort of patients with multiple comorbidities and coinfections<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d21151e2237>In contrast, Ford <i>et al</i>. observed that patients with pre-engraftment VREB had a relatively good prognosis, with one-year survival of 80%. Although pre-engraftment bacteremia with any organism was associated with worse OS, risk factors and survival outcomes in patients with pre-engraftment VREB did not significantly differ when compared to those in patients with pre-engraftment bacteremia due to other organisms, including vancomycin-susceptible <i>enterococcus</i> (VSE)<sup><a href="#ref-8">8</a></sup>. The group at the Mayo Clinic<sup><a href="#ref-9">9</a></sup> observed that only one of the six patients with VREB and fatal outcome died within the first 100 days post-HSCT and no death was directly related to VRE infection. This lower mortality occurred despite delayed use of anti-VRE antibiotics (median two days after the onset of bacteremia) in 7(63%) of the 11 patients with VRE BSI. This observation is in line with the findings of Ford and colleagues and others<sup><a href="#ref-8">8</a>,<a href="#ref-23">23</a>,<a href="#ref-25">25</a></sup> and suggests that the effects of VRE may not be related to its virulence but instead that VREB may be a surrogate marker of comorbidity burden and poor overall status. Mortality is likely associated with the severity and duration of immunosuppression and other comorbidities.</p><p class="" id=d21151e2264>In contrast to pre-engraftment VREB, post-engraftment VREB carried higher morbidity and mortality in the study by Ford <i>et al</i>. Compared to pre-engraftment VREB and bacteremia with other organisms, post-engraftment VRE BSI carried the highest mortality and healthcare costs. However, patients with post-engraftment bacteremia had significant life-threatening comorbidities (severe GVHD, leukemic recurrence, and multi-organ failure).</p></div><div class=section><a name=d21151e2270 class=n-a></a><h3 class=section-title>Impact of vancomycin-resistant enterococci colonization on hematopoietic stem cell transplant outcomes</h3><p class="" id=d21151e2274>The impact of VRE colonization on VRE BSI and HSCT outcomes has been assessed with some relative degree of consensus in recently conducted studies. The group in Utah (Ford <i>et al</i>.) observed that pre-HSCT colonization was associated with an increased incidence of subsequent colonization and of HSCT-associated VREB but not with worse survival or increase in length of stay (LOS)<sup><a href="#ref-8">8</a></sup> (<a href="#T1">Table 1</a>).</p><p class="" id=d21151e2287>In line with these findings, Hefazi <i>et al</i>.<sup><a href="#ref-9">9</a></sup> noted that pre-transplant VRE colonization was associated with increased rates of VRE BSI (11% versus 3%, <i>P</i> = 0.03) and hospitalization (85% versus 71%, <i>P</i> = 0.02) within 100 days of HSCT and was an independent risk factor for these outcomes (HR 3.9 [1.0–17], <i>P</i> = 0.04 and HR 2.3 [1.1–5.4], <i>P</i> = 0.02, respectively). However, it had no significant impact on the incidence of FN, BSI with other bacteria, ICU admission, mortality (10% versus 7%), or OS, suggesting VRE colonization may only be a surrogate marker for poor outcomes. In contrast, VRE colonization occurring within the first 100 days after HSCT was an independent risk factor for worse OS when compared to those who remained free of colonization. This group also had higher rates of death due to relapse (29% versus 9%, <i>P</i> = 0.03) and chronic GVHD (19% versus 6%, <i>P</i> = 0.07). In patients with FN, however, OS was not affected by the presence of VRE colonization. These two studies are in agreement with others<sup><a href="#ref-10">10</a>,<a href="#ref-12">12</a></sup> that found that pre-transplant VRE colonization had no impact on post-HSCT survival in the absence of occurrence of VRE BSI, but they contrast to the report of Zirakzadeh <i>et al</i>.<sup><a href="#ref-17">17</a></sup>, who reported that colonization was an independent risk factor for 100-day post-HSCT mortality.</p><p class="" id=d21151e2330>In their examination of the gut microbiota in HSCT patients, Taur and colleagues at the MSKCC demonstrated that microbial diversity at the time of stem cell engraftment predicts HSCT survival<sup><a href="#ref-58">58</a></sup>. Decreased diversity and intestinal domination by <i>enterococc</i>i not only correlates with the spectrum of antibiotics administered to patients but also predicts reduced survival. Ongoing studies are investigating whether reconstitution of intestinal microbiota using fecal microbial transplantation following allogeneic HSCT may provide an approach to optimize clinical outcomes and survival (clinicaltrials.gov identifier: NCT02269150).</p><p class="" id=d21151e2340>Thus, among allogeneic HSCT patients, VRE colonization is a risk factor and a precondition for VREB, especially when present in the GI tract as a dominant organism. VREB is associated with decreased survival (especially post-engraftment) but not with attributable mortality, with death largely related to comorbidities. Autologous HSCT patients may have a prevalence of VRE colonization similar to that seen in allogeneic HSCT patients, but they appear to have a lower risk of bacteremia without associated increased risk of mortality.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e2345>Prevention of vancomycin-resistant enterococci acquisition and infection</h2><p class="" id=d21151e2348>With the emergence of VRE as a leading cause of BSI in HSCT recipients, as well as healthcare-associated infections in general, preventive strategies emerge as the key to controlling the spread of VRE infection in HSCT units. Prevention activities usually combine hand hygiene, environmental cleaning/disinfection, contact isolation, and surveillance<sup><a href="#ref-59">59</a></sup>. There is, however, variation across centers in the application of infection control measures for HSCT recipients<sup><a href="#ref-60">60</a></sup>.</p><div class=section><a name=d21151e2359 class=n-a></a><h3 class=section-title>Cleaning and decontamination</h3><p class="" id=d21151e2363>Hand hygiene programs paired with feedback systems including electronic surveillance have been demonstrated in hematology units to increase compliance and to significantly reduce the nosocomial transmission of VRE<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>.</p><p class="" id=d21151e2373>In an Australian study conducted in high VRE risk wards, the incorporation of bleach-based disinfection markedly reduced VRE environmental contamination by 66.4% (<i>P</i> = 0.012) and also resulted in lower rates of newly acquired VRE as well as VREB by 25% (<i>P</i> = 0.016) and 83% (<i>P</i> &lt;0.001), respectively<sup><a href="#ref-63">63</a></sup>. Daily bathing with 2% chlorhexidine (CHG) has been proposed to prevent bacterial colonization in critically ill patients, and its impact has been studied particularly in ICU patients, in whom CHG has been shown to reduce VRE burden<sup><a href="#ref-64">64</a>–<a href="#ref-66">66</a></sup>.</p><p class="" id=d21151e2396>Limited and controversial data are available in HSCT patients. Although one study failed to show any benefit of use of CHG wipes in hematology-oncology patients<sup><a href="#ref-67">67</a></sup>, a contemporaneous multicenter randomized trial including HSCT patients demonstrated a 25% (<i>P</i> = 0.05) reduction in acquisition of VRE colonization but no significant reduction in VREB<sup><a href="#ref-68">68</a></sup>. In a quasi-experimental study, Mendes and colleagues evaluated the impact of prolonged exposure to CHG (using shower bath and liquid soap formula) on the incidence of VRE colonization and of infection in a BMT unit and found a significant (<i>P</i> = 0.001) reduction in the rate of both<sup><a href="#ref-69">69</a></sup>. This occurred despite the absence of a substantial effect on overall hospital rates of VRE or on the incidence of infection and colonization with multidrug-resistant (MDR) GN bacteria<sup><a href="#ref-70">70</a></sup>.</p><p class="" id=d21151e2422>Novel methods for environmental decontamination have emerged with promising results, including the use of hydrogen peroxide vapor<sup><a href="#ref-71">71</a></sup>, copper alloy surfaces<sup><a href="#ref-72">72</a></sup>, or pulsed-xenon ultraviolet room disinfection<sup><a href="#ref-73">73</a></sup>. These techniques are currently being evaluated in an ongoing trial with HSCT recipients (clinicaltrials.gov identifier: NCT02463214).</p></div><div class=section><a name=d21151e2437 class=n-a></a><h3 class=section-title>Surveillance strategies</h3><p class="" id=d21151e2441>The benefit and cost effectiveness of routine VRE surveillance, as well as the optimal testing frequency, are controversial and it has not been universally adopted in HSCT units. The Society for Healthcare Epidemiology of America (SHEA) as well as the American Society of Bone Marrow Transplantation (ASBMT) infection prevention guidelines from 2009 limit their relevant recommendation to the following: “VRE rectal or stool active surveillance cultures to identify colonized patients can be considered if there is evidence for ongoing transmission of VRE on a HCT unit”<sup><a href="#ref-59">59</a>,<a href="#ref-74">74</a></sup>.</p><p class="" id=d21151e2451>Nonetheless, pre-HSCT screening can identify a high proportion of patients at risk of VREB. The variability in sample collection technique and poor sensitivity of culture-based methods for the detection of VRE is well recognized<sup><a href="#ref-75">75</a></sup>, but few studies have evaluated PCR techniques in HSCT recipients. In centers using PCR, up to 90–100% of patients developing bacteremia had previously been colonized<sup><a href="#ref-7">7</a>,<a href="#ref-9">9</a>,<a href="#ref-17">17</a></sup>. Hefazi <i>et al</i>. also showed that the likelihood of VRE being the etiologic organism of GP bacteremia in FN patients was 2.5 times higher in patients previously colonized, arguing for surveillance to guide empirical therapy in FN patients<sup><a href="#ref-9">9</a></sup>.</p></div><div class=section><a name=d21151e2475 class=n-a></a><h3 class=section-title>Barrier precautions and isolation</h3><p class="" id=d21151e2479>Contact precautions (CPs) against VRE include the use of single-patient rooms and of gowns and gloves during patient contact<sup><a href="#ref-59">59</a></sup>. Barrier precautions and contact isolation have, however, not been clearly shown to be effective at preventing VRE colonization<sup><a href="#ref-29">29</a>,<a href="#ref-76">76</a></sup>. Nevertheless, these are widely used in HSCT recipients, based on extrapolation from the standard practice for containment of other resistant bacteria rather than direct evidence. Literature has provided evidence supporting the use of CPs for the prevention of resistant bacteria including VRE in patients with hematologic malignancies<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup>, albeit there are concerns for biased reporting of positive results and studies that often evaluate multiple interventions<sup><a href="#ref-8">8</a></sup>. The systematic implementation of CPs has also been questioned for lack of proven efficacy and collateral adverse effects including associated stigma leading to poorer patient care<sup><a href="#ref-79">79</a>–<a href="#ref-82">82</a></sup>. Two cluster-randomized trials evaluated the efficacy of active surveillance for MRSA and VRE colonization and the universal use of gowns and gloves (compared to targeted use in colonized patients): neither intervention resulted in a difference in MRSA and VRE acquisition<sup><a href="#ref-76">76</a>,<a href="#ref-83">83</a></sup>. More than 40 hospitals in the United States have abandoned the implementation of universal CPs. Elimination of this measure has resulted in no change in rates of VRE infection in several recent studies and could also result in significant cost saving and decreased healthcare worker time<sup><a href="#ref-84">84</a>–<a href="#ref-86">86</a></sup>. Selective use of CPs for patients at high risk of transmission—for instance, those with draining wounds or diarrhea—or for healthcare professionals performing high-risk patient care activities may be more efficient<sup><a href="#ref-87">87</a></sup>.</p><p class="" id=d21151e2530>VRE-colonized patients usually stay colonized for an extended period of time once initially detected. HSCT recipients with previous VRE colonization or infection should continue to receive CPs during hospital readmissions. Compliance can be facilitated by the use of electronic health records programmed to provide alerts<sup><a href="#ref-59">59</a></sup>. However, data providing guidance regarding the optimal duration of precautions for HSCT recipients with a history of VRE are lacking. Criteria for discontinuation of CPs is determined according to individual institutional protocols (e.g. three consecutive sets of screening cultures negative for VRE obtained on separate days for a patient not on effective anti-VRE agents)<sup><a href="#ref-74">74</a></sup>.</p><p class="" id=d21151e2541>Almyroudis and colleagues recently evaluated the impact of discontinuing systemic surveillance and CPs on the incidence of vancomycin-resistant <i>Enterococcus faecium</i> bacteremia in patients with hematologic malignancies and HSCT recipients<sup><a href="#ref-88">88</a></sup>. During the first period of the study (2008–2011), the local VRE prevention protocol included weekly fecal surveillance of all patients admitted to the hospital and lifelong contact isolation of colonized patients. However, the authors found that neither colonization nor bacteremia incidence was lowered by strict implementation of these measures<sup><a href="#ref-29">29</a></sup>. Moreover, they did molecular analysis of fecal and blood isolates for genetic similarity to define clonality and to identify common sources of infection or modes of transmission to find a primarily sporadic pattern of VRE acquisition in which the majority of the patients harbored unique VRE strains. Discontinuation of strict precautions and surveillance did not affect the incidence of VREB over the following three-year period. They also observed that the use of levofloxacin prophylaxis during neutropenia and daily CHG bathing had no effect on either (<i>P</i> &gt;0.05). The use of antibiotics, incidence of MRSA bacteremia, and <i>C. difficile</i> infection remained stable during the two time-periods (<i>P</i> &gt;0.05).</p></div><div class=section><a name=d21151e2565 class=n-a></a><h3 class=section-title>Modification of microbiota</h3><p class="" id=d21151e2569>In the past, selective digestive tract decontamination has been used in hematology and ICU units to prevent GN bacteremia<sup><a href="#ref-89">89</a></sup>. An opposite strategy aiming to restore microbiota diversity using autologous fecal microbiota transplantation is being explored in clinical trials to prevent breakthrough infections with dominant MDR organisms like VRE (clinicaltrials.gov identifier: NCT03061097). The anecdotal use of short courses of linezolid or daptomycin paired with other decolonization methods—including the use of polyethylene glycol for bowel preparation to wash-out the fecal bacterial population prior to the administration of antibacterials—has not been tested in large cohorts of HSCT recipients<sup><a href="#ref-90">90</a></sup>.</p></div><div class=section><a name=d21151e2580 class=n-a></a><h3 class=section-title>Prophylactic antibiotics</h3><p class="" id=d21151e2584>The rate of progression from VRE colonization to bacteremia in the early post-transplant period and the high associated mortality in earlier studies have led to considerations of administration of prophylactic antibiotics at the time of transplantation. Wong <i>et al</i>. demonstrated only temporary (for up to two weeks) suppression of GI VRE colonization with the investigational non-absorbable glycolipodepsipeptide ramoplanin<sup><a href="#ref-91">91</a>,<a href="#ref-92">92</a></sup>. The addition of systemic anti-VRE agents such as linezolid or daptomycin to the peri-transplant prophylactic regimen is an alternative intervention but with non-negligible associated risks, including emergence of resistances<sup><a href="#ref-93">93</a>,<a href="#ref-94">94</a></sup>, and associated toxicities, notably linezolid-induced cytopenias. The 2009 ASBMT guidelines for the prevention of infections in HSCT recipients recommends against the use of anti-GP agents for prophylaxis<sup><a href="#ref-74">74</a></sup>.</p></div><div class=section><a name=d21151e2608 class=n-a></a><h3 class=section-title>Antibiotic stewardship</h3><p class="" id=d21151e2612>Antibiotic exposure is a key risk factor for VRE colonization and infection in hematology patients<sup><a href="#ref-29">29</a>,<a href="#ref-35">35</a>,<a href="#ref-95">95</a></sup>. Antimicrobial stewardship programs (ASPs) are therefore crucial as a complement to infection control strategies<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a></sup>.</p><p class="" id=d21151e2632>The precise association between vancomycin use—both intravenous and oral—and VRE colonization and infection remains unclear owing to conflicting data from animal models and clinical studies<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a>,<a href="#ref-50">50</a>,<a href="#ref-52">52</a>,<a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>. Al Nassir and colleagues observed that VRE-colonized patients treated for diarrhea due to <i>C. difficile</i> with oral vancomycin (and/or metronidazole) had persistence of VRE intestinal overgrowth (<i>P</i> &lt;0.049)<sup><a href="#ref-37">37</a></sup>. In a meta-analysis by Carmeli <i>et al</i>. of 15 studies with optimal control groups, vancomycin exposure conferred a 2.7-fold increased risk of VRE acquisition<sup><a href="#ref-100">100</a></sup>. However, a subsequent individual case-control study by the same group failed to show such an association<sup><a href="#ref-49">49</a></sup>. Therefore, the effect of restricting vancomycin on acquiring clinically significant VRE at the population level is still unclear. A large ecologic study found that vancomycin was the most significant 'modifiable' risk factor resulting in VRE colonization<sup><a href="#ref-50">50</a></sup>, yet a systematic review was not able to conclude that restriction of vancomycin prescribing had any effect on the prevalence and incidence of VRE colonization and infection in US hospitals<sup><a href="#ref-101">101</a></sup>. Nevertheless, as demonstrated by Taur <i>et al</i>.<sup><a href="#ref-36">36</a></sup>, intestinal domination of VRE driven by antimicrobial pressure precedes bacteremia. To prevent this, the ASBMT guidelines of infection prevention recommend minimization of the use and duration of vancomycin, agents with anti-anaerobic coverage (e.g. metronidazole), and third-generation cephalosporins<sup><a href="#ref-74">74</a></sup>. Restricted use of broad-spectrum antibiotics and early implementation of targeted therapies<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a>,<a href="#ref-102">102</a></sup> can effectively reduce VRE overgrowth, colonization, and subsequent infection.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e2708>Treatment</h2><div class=section><a name=d21151e2711 class=n-a></a><h3 class=section-title>Daptomycin</h3><p class="" id=d21151e2715>The current treatment of invasive VRE infections primarily revolves around the use of either daptomycin or linezolid. Daptomycin has the potential advantages of having bactericidal activity against many strains of VRE as well as a relative lack of toxicity and of drug–drug pharmacokinetic (PK) interactions. Its disadvantages include ready selection of non-susceptible strains and high acquisition cost.</p><p class="" id=d21151e2718>Reduced susceptibility of VRE to daptomycin is an increasingly encountered phenomenon and may occur subsequent, or during exposure, to the antibiotic in the clinical setting<sup><a href="#ref-103">103</a></sup>. Thus, DiPippo and colleagues found that exposure to daptomycin within the prior 90 days was associated with a significant risk that subsequent <i>E. faecium</i> bacteremia will be due to a daptomycin non-susceptible (DNS) strain<sup><a href="#ref-104">104</a></sup>. Furthermore, <i>in vitro</i> studies found that, with commonly used doses of &lt;10 mg/kg/day, free drug Cmax values usually fall within the mutant selection window<sup><a href="#ref-105">105</a></sup>. In addition, many isolates with MICs of 3-4 mcg/mL (isolates with MIC &gt;4 mcg/mL are non-susceptible) carry mutations, especially in <i>liaFSr</i>, that are associated with loss of daptomycin bactericidal activity<sup><a href="#ref-106">106</a></sup>, and exposure of these strains to daptomycin concentrations consistent with administration of ≤10 mg/kg/day allowed regrowth<sup><a href="#ref-107">107</a></sup>.</p><p class="" id=d21151e2751>In a prospective cohort study of a general patient population, high-dose (≥9 mg/kg/day) daptomycin administration was associated with greater survival than was lower-dose (6–9 mg/kg/day) administration<sup><a href="#ref-108">108</a></sup>. Similarly, a national retrospective cohort study in the Veterans Administration system found that doses of ≥10 mg/kg/day were associated with improved survival relative to doses of 8 and 6 mg/kg/day<sup><a href="#ref-109">109</a></sup>. In contrast, Shukla and colleagues found, in a multicenter retrospective cohort study, that, while an MIC of 3–4 mcg/mL (by ETest, but not by standard broth microdilution) was an independent predictor of microbiologic failure, initial dosing of daptomycin of ≥8 mcg/mL did not improve outcomes<sup><a href="#ref-110">110</a></sup>. Of note is that the only independent risk factor for failure other than MIC of 3–4 mcg/mL was immunosuppression, which was present in 48 of the 62 patients with vancomycin-resistant <i>E. faecium</i> bacteremia; 26 of the 48 were neutropenic and 17 were organ transplant recipients.</p><p class="" id=d21151e2769>In a smaller retrospective single-center study limited to HSCT patients and/or patients with hematologic malignancies with VRE (all <i>E. faecium</i>) bacteremia, daptomycin ETest MIC of 3–4 mcg/mL, when compared to lower MICs, with regard to 30-day all-cause mortality inexplicably had an adjusted HR of 0.27 (95% confidence interval [CI] 0.07–1.06, <i>P</i> = 0.06)<sup><a href="#ref-111">111</a></sup>. Treatment with daptomycin doses &gt;6 mg/kg/day (median dose of 8.1 mg/kg/day) was not significantly associated with less microbiological failure, but the number of patients for whom dosing data were available was limited.</p><p class="" id=d21151e2782>These studies, taken as a whole, suggest, but do not clearly demonstrate, that daptomycin doses of 6 mg/kg/day may be therapeutically inadequate and may increase the likelihood of selection of resistant mutants and that higher doses (e.g. 10 mg/kg/day) may be preferable.</p></div><div class=section><a name=d21151e2785 class=n-a></a><h3 class=section-title>Linezolid</h3><p class="" id=d21151e2789>Linezolid has excellent oral bioavailability but is bacteriostatic, has potential toxicity (including hematologic), and also has a number of important interactions with other drugs.</p><p class="" id=d21151e2792>However, the distinction between bacteriostatic and bactericidal activity of an antibiotic is, to some extent, arbitrary<sup><a href="#ref-112">112</a></sup>. Furthermore, while many clinicians believe that bactericidal activity is preferred in bacteremic patients with neutropenia, evidence to support this appears to be lacking<sup><a href="#ref-112">112</a></sup>, with the exception of endocarditis.</p><p class="" id=d21151e2803>Although prolonged linezolid therapy in excess of 14 days carries a risk of development of cytopenias, particularly thrombocytopenia, in all patient groups, its effects in patients recovering from chemotherapy-induced cytopenias raise particular concern. A series of studies have examined the hematologic safety of linezolid in chemotherapy-induced neutropenia including in the pre-engraftment period of HSCT. A retrospective analysis of 43 HSCT and hematologic malignancy patients with VREB (42 due to <i>E. faecium</i>) treated with either linezolid (n = 29) for a median of 11.5 days or daptomycin (n = 43) for a median of 13.0 days found no significant difference in outcomes or in duration of thrombocytopenia or neutropenia<sup><a href="#ref-113">113</a></sup>. In a retrospective analysis of patients receiving induction chemotherapy for newly diagnosed acute myelogenous leukemia, the median times to neutrophil recovery in those who received ≥14 days of linezolid or vancomycin were 29 days and 26 days (<i>P</i> = 0.487), respectively<sup><a href="#ref-114">114</a></sup>. This was true despite the fact that linezolid was administered for a duration of 27 days compared to 16 days (<i>P</i> &lt;0.001) of vancomycin administration. In a randomized trial, patients with FN received either linezolid or vancomycin for GP coverage; these were administered for means of 11.4 days and 11.5 days, respectively<sup><a href="#ref-115">115</a></sup>. While there was no difference in time to platelet recovery, neutrophil recovery was modestly delayed. Finally, no significant difference was found in time to engraftment in allogeneic HSCT recipients who received either linezolid for a median of 14 days (range: 7–34 days) or vancomycin for a median of 16 days (range: 8–33 days)<sup><a href="#ref-116">116</a></sup>. In a study of 100 HSCT and hematologic malignancy patients with fever and neutropenia, 35 of whom received linezolid beginning after persistence of FN for 48 hours while the remainder continued to receive a glycopeptide, severe neutropenia occurred significantly less frequently in the linezolid recipients<sup><a href="#ref-117">117</a></sup>.</p><p class="" id=d21151e2836>Resistance to linezolid may occur, especially after prolonged exposure, but remains quite infrequent. Thus, surveillance programs found that only 0.78% of <i>Enterococci</i> isolates in the US and 0.22% worldwide were linezolid resistant<sup><a href="#ref-118">118</a></sup>.</p></div><div class=section><a name=d21151e2846 class=n-a></a><h3 class=section-title>Linezolid versus daptomycin: targeted therapy</h3><p class="" id=d21151e2850>Recent reports provide conflicting results regarding the relative efficacy of linezolid and daptomycin in the treatment of VREB in general hospital populations.</p><p class="" id=d21151e2853>A retrospective analysis of patients with VREB treated at Veterans Administration Medical Centers (VAMC) across the country from 2004–2013 examined outcomes in 319 patients treated with linezolid and 325 given daptomycin<sup><a href="#ref-119">119</a></sup>. There was a statistically significant relationship between the use of linezolid and treatment failure (adjusted relative risk [RR] 1.15, 95% CI 1.02–1.30, <i>P</i> = 0.026), as well as 30-day mortality and microbiologic failure.</p><p class="" id=d21151e2863>In a retrospective national VAMC study of 2,630 evaluable patients with VREB, one-fifth of whom were included in the study described above<sup><a href="#ref-119">119</a></sup>, linezolid therapy (n = 1,348) was associated, after matching by propensity score, with increased mortality relative to daptomycin (n = 1,055) treatment (RR 1.13, 95% CI 1.02–1.26, <i>P</i> = 0.015)<sup><a href="#ref-120">120</a></sup>. In addition, the 227 patients initially given linezolid but whose therapy was changed to daptomycin also had lower mortality than those treated with only linezolid (RR 1.29, 95% CI 1.03–1.63, <i>P</i> = 0.021). Daptomycin treatment was associated with significantly lower mortality only in patients with endocarditis (6.6% of the total cohort). Only a minority of patients were significantly immunocompromised, including those who had received solid-organ transplant (2.7%), those with hematologic malignancy (15.9%), and those with neutropenia (7.9%). The median durations of bacteremia in daptomycin and linezolid recipients were three days and two days (<i>P</i> &lt;0.001), respectively. An important potential confounder in this analysis was the potential role of daptomycin synergy with β-lactam antibiotics, which were received by approximately four-fifths of patients.</p><p class="" id=d21151e2883>In contrast to the VAMC studies, two recent meta-analyses reached very different conclusions. A meta-analysis that included 11 retrospective cohort studies available by November 2015 with a total of 1,339 patients with all daptomycin recipients receiving ≥6 mg/kg/day found no significant differences in overall crude mortality, clinical cure, microbiological cure, or incidence of relapse when compared to linezolid in the treatment of VREB<sup><a href="#ref-121">121</a></sup>. The authors pointed out that the individual studies were heterogeneous and had relatively small sample sizes.</p><p class="" id=d21151e2890>Another meta-analysis of 13 studies published before 1 January 2014 that included 532 daptomycin recipients and 656 given linezolid found that daptomycin therapy was associated with greater mortality (odds ratio [OR] 1.43, 95% CI 1.09–1.86, <i>P</i> = 0.009)<sup><a href="#ref-122">122</a></sup>. There was, however, no significant difference in microbiological cure. Heterogeneity of included studies was detected and all studies were retrospective with relatively small sample sizes.</p><p class="" id=d21151e2901>Comparative data related to neutropenic and/or HSCT patients is extremely limited. In a single center retrospective analysis of 72 HSCT and hematologic malignancy patients with VREB, 42 of which were due to <i>E. faecium</i>, 43 received daptomycin (median dose: 4.5 mg/kg every 24–48 hours) and 29 received linezolid<sup><a href="#ref-113">113</a></sup>. There was no significant difference in success rates. Similarly, Patel and colleagues reported their single-center retrospective analysis of adult oncology patients with VREB, with 32 and 33 having received daptomycin and linezolid, respectively<sup><a href="#ref-123">123</a></sup>. Of the total of 65 patients, 36 (55.4%) had acute leukemia, 11 (6.9%) were HSCT recipients, and 42 (64.6%) were neutropenic at the start of antibiotic therapy. Microbiological cure was achieved in 22 (71%) daptomycin recipients and 26 (75.6%) of those who received linezolid, while 8 of the 33 (25.8%) of the former and 7 of the 32 (20.6%) of the latter died.</p></div><div class=section><a name=d21151e2915 class=n-a></a><h3 class=section-title>Empiric therapy</h3><p class="" id=d21151e2919>The 2010 IDSA guidelines recommend that consideration be given to modification of the initial empiric therapy for patients who are at risk of VRE infection with risk factors including colonization or prior infection with the organism as well as the presence of ‘high endemicity’ of VRE within the treating institution<sup><a href="#ref-102">102</a></sup>. In such circumstances, they recommend the early administration of either linezolid or daptomycin. The 2016 ESMO guidelines do not address the issue<sup><a href="#ref-124">124</a></sup>.</p><p class="" id=d21151e2930>Lisboa and colleagues retrospectively examined outcomes in 100 VRE-colonized HSCT and hematologic malignancy patients with fever and neutropenia to determine the effect of empiric linezolid administration on outcome<sup><a href="#ref-117">117</a></sup>. The policy at their institution was to consider the use of linezolid in colonized patients with persisting fever after 48 hours of administration of an antibiotic with broad-spectrum GN coverage plus a glycopeptide. The latter was discontinued when linezolid was prescribed. A total of 14 episodes of VREB subsequently occurred in the 65 patients who continued to receive a glycopeptide, while none occurred in the 35 patients switched to linezolid. The pre-emptive administration of linezolid, however, had no significant effect on overall mortality.</p></div><div class=section><a name=d21151e2937 class=n-a></a><h3 class=section-title>Other antibiotics</h3><p class="" id=d21151e2941><b><i>Quinupristin/dalfopristin</i>.</b> In 2010, FDA approval of quinupristin/dalfopristin for the treatment of bacteremia due to <i>E. faecium</i> was withdrawn because of lack of evidence of efficacy.</p><p class="" id=d21151e2951><b><i>Tedizolid</i>.</b> Tedizolid shares its mechanism of action with linezolid but may be more potent<sup><a href="#ref-125">125</a>–<a href="#ref-127">127</a></sup>. Its capability of interacting with the 23S ribosomal subunit with higher affinity allows it to maintain activity even in the presence of target site modifications conferring linezolid resistance. Isolates with the chloramphenicol-florfenicol resistance (<i>cfr</i>) gene retain tedizolid MICs &lt;4 mg/L<sup><a href="#ref-128">128</a></sup>. MICs for tedizolid are frequently fourfold to eightfold lower than those of linezolid, and, although not routinely reported, can be inferred from linezolid MIC values<sup><a href="#ref-129">129</a></sup>. From the PK standpoint, tedizolid has a more favorable profile. With a longer half-life and oral bioavailability above 90%, it can be given once daily<sup><a href="#ref-126">126</a></sup>, orally or intravenously, and does not require dose adjustments with renal or hepatic impairment<sup><a href="#ref-130">130</a></sup>.</p><p class="" id=d21151e2985>In two phase III clinical trials, ESTABLISH-1 and ESTABLISH-2, tedizolid was non-inferior to linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSIs)<sup><a href="#ref-131">131</a>,<a href="#ref-132">132</a></sup>. Patients receiving “long-term systemic immunosuppressive therapy” were excluded. These studies led to the drug’s FDA approval for this indication in 2014. The use of tedizolid in systemic VRE infections has not, however, been evaluated. Tedizolid may offer a better side effect profile than does linezolid. Prolonged oxazolidinone therapy is associated with toxicities, some of which derive from impairment of protein synthesis at the mitochondrial level, including lactic acidosis and both peripheral and optic neuropathy, but most commonly myelosuppression<sup><a href="#ref-133">133</a></sup>. Some data suggest a lack of association of tedizolid with impaired eukaryotic mitochondrial function<sup><a href="#ref-134">134</a></sup>. With the potential for lesser myeloid toxicity, tedizolid may be beneficial for long-term therapy, especially in patients with hematological malignancy. A recent study examined the hematological effects of 21 days of treatment with different doses of tedizolid (200 mg, 300 mg, and 400 mg daily) compared to standard linezolid doses (600 mg twice daily) and placebo in groups of eight patients. Progressive tedizolid-induced thrombocytopenia occurred in a dose-dependent manner, and the effects of tedizolid at 400 mg daily were similar to those of linezolid. No adverse platelet outcome was observed in the standard tedizolid dose group<sup><a href="#ref-135">135</a></sup>.</p><p class="" id=d21151e3007><b><i>Telavancin</i>.</b> Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin with dose-dependent bactericidal activity against <i>enterococ</i>ci. It inhibits peptidoglycan synthesis by binding to D-alanyl-D-alanine and disrupts the cell membrane, increasing its permeability<sup><a href="#ref-136">136</a></sup>. Telavancin retains activity against GP organisms with decreased susceptibility to vancomycin. It is active against vancomycin-susceptible <i>Enterococcus faecalis</i> and <i>E. faecium</i> (MIC90 ≤1 µg/mL)<sup><a href="#ref-137">137</a></sup>, but, when tested against VRE strains, telavancin MICs were significantly elevated (MIC90 8–16 µg/mL)<sup><a href="#ref-138">138</a></sup>. Telavancin showed more potent activity against <i>vanB</i> strains (MIC ≤2 µg/mL) than against <i>vanA</i> strains (MIC ≤16 µg/mL)<sup><a href="#ref-139">139</a></sup>. Telavancin has a relatively prolonged half-life of 6.9–9.1 hours that allows for daily dosing, usually of 10 mg/kg/day. Dosage adjustments (7.5 mg/kg/day) are required for patients with creatinine clearance &lt;50 mL/minute. Based on its comparable efficacy to vancomycin for the treatment of complicated skin and skin structure infection (SSTI) and pneumonia caused by GP cocci, telavancin received FDA approval for these indications in 2009 and 2013, respectively<sup><a href="#ref-140">140</a>,<a href="#ref-141">141</a></sup>. However, adverse events, including nephrotoxicity, which is comparable to that of vancomycin, have limited its use. No clinical data are available addressing the use of telavancin in invasive VRE infections and bacteremia. Finally, since most vancomycin-resistant <i>E. faecium</i> isolates possess the <i>vanA</i> gene, its role in the treatment of invasive VRE disease is limited.</p><p class="" id=d21151e3060><b><i>Dalbavancin</i>.</b> As a lipoglycopeptide, dalbavancin possesses a long lipophilic side chain that inserts into the bacterial cell membrane, enhances its affinity to the target site, and markedly prolongs its half-life. Its dual mechanism of action increases its <i>in vitro</i> activity against <i>enterococci</i><sup><a href="#ref-142">142</a></sup>. In an evaluation of nearly 82,000 GP isolates, dalbavancin was over 16-fold more potent than vancomycin. MIC90 values against vancomycin-sensitive <i>E. faecalis</i> and <i>E. faecium</i> were of 0.06 and 0.12 mg/L, respectively. However, similar to telavancin, dalbavancin does not bind peptidoglycan precursors ending in D-Ala-D-Lac and only has significant activity against VRE isolates with the uncommonly encountered (in the US) <i>vanB</i> phenotype<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>, thus limiting its usefulness.</p><p class="" id=d21151e3094>Dalbavancin was approved by the US FDA in 2013 for the treatment of ABSSSI<sup><a href="#ref-145">145</a></sup>. Its 181-hour half-life allows for weekly administration; it has a dual route of elimination demanding dose adjustments in renal dysfunction but not in hepatic failure. When evaluated in clinical trials for the treatment of SSTI, dalbavancin once weekly demonstrated non-inferiority with similar rates of both safety and efficacy compared with linezolid twice daily<sup><a href="#ref-145">145</a>–<a href="#ref-147">147</a></sup>. Its efficacy compared to that of vancomycin was evaluated in 75 patients with catheter-related BSIs caused by GP bacteria<sup><a href="#ref-148">148</a></sup>. Although overall efficacy was higher with dalbavancin (87% versus 50%), <i>enterococci</i> bacteremia was underrepresented in the study, with only two patients in the dalbavancin arm and three in the vancomycin arm, and organism-specific efficacy was not mentioned. Moreover, the role of dalbavancin, as with telavancin, is limited by its relatively lesser activity against <i>vanA</i>-carrying strains.</p><p class="" id=d21151e3118><b><i>Oritavancin</i>.</b> Oritavancin, approved by the FDA for ABSSSI in 2014, appears to be more promising for VRE infections. This antibiotic is a synthetic derivative of the natural glycopeptide chloroeremomycin. Its structural additions allow improved binding to the peptidoglycan precursor D-Ala-D-Ala but also to D-Ala-D-Lac necessary for the inhibition of cell wall synthesis and yielding significant activity against VRE carrying either <i>vanB</i> or <i>vanA</i><sup><a href="#ref-149">149</a>,<a href="#ref-150">150</a></sup>. This improved binding to the cell wall assembly apparatus, coupled with its membrane effects as the result of binding of its lipophilic side chain, mediates potent bactericidal activity against both growing cells and biofilms.</p><p class="" id=d21151e3137>Morrissey and colleagues collected 866 GP bacterial isolates from several countries in western Europe to evaluate their susceptibilities to oritavancin compared to other commercially available agents. Oritavancin was capable of inhibiting all isolates, including 101 VRE, at concentrations of 0.25 mg/L or less, confirming the potent <i>in vitro</i> activity of the drug even against GP bacteria resistant to newer agents like linezolid and daptomycin<sup><a href="#ref-151">151</a></sup>.</p><p class="" id=d21151e3147>A terminal half-life of 393 hours, together with its post-antibiotic effect, allows single-dose administration of this drug for many infections<sup><a href="#ref-152">152</a></sup>. Although dose adjustments are not needed in mild-to-moderate renal and hepatic impairment, dosing in severe hepatic and renal dysfunction has not been studied. In the initial clinical trial evaluating the safety and efficacy of oritavancin for the treatment of ABSSSI, patients received oritavancin 1,200 mg as a single dose or vancomycin twice daily for 7–10 days. Both safety and efficacy end points, including reduction of lesion size, were comparable in both arms. Compared to a dose of 12 mg/kg/day of daptomycin, a single 1,200 mg dose of oritavancin demonstrated less rapid but more sustained bactericidal activity against vancomycin-resistant <i>E. faecium</i> isolates after 72 hours in an <i>in vitro</i> PK/pharmacodynamic (PD) model<sup><a href="#ref-153">153</a></sup>. However, there are no clinical data available addressing the use of oritavancin in VRE invasive infections, including VREB, and the optimal dosing regimen for these indications is unknown<sup><a href="#ref-151">151</a></sup>. Finally, the degree and mechanisms of resistance to oritavancin are not fully characterized. Thus, although promising, the role of oritavancin in the treatment of VRE infections remains to be established.</p><p class="" id=d21151e3168><b><i>Tigecycline</i>.</b> Tigecycline is a minocycline-derived glycylcycline with an N-alkyl-glycylamido group substitution, which allows it to have activity against tetracycline-resistant GN and GP organisms, including VRE<sup><a href="#ref-154">154</a></sup>. Tigecycline is highly active against <i>enterococci in vitro</i>. In a recent surveillance study<sup><a href="#ref-155">155</a></sup>, all <i>Enterococcus</i> species were sensitive to tigecycline with an MIC90 of 0.25 µg/mL, which is the breakpoint for <i>E. faecalis</i> (also known as VSE) established by the FDA and European Committee on Antimicrobial Susceptibility Testing<sup><a href="#ref-156">156</a>,<a href="#ref-157">157</a></sup>. Susceptibility breakpoints have not been set for other <i>Enterococcus</i> species such as <i>E. faecium</i>.</p><p class="" id=d21151e3206>Tigecycline, which is bacteriostatic, has a large volume of distribution (range: 7–17 L/kg), leading to high concentrations in tissue but low concentrations in serum<sup><a href="#ref-154">154</a></sup>. These characteristics partially explain why it is not indicated for the treatment of VRE infections and should not be given in monotherapy for VREB<sup><a href="#ref-158">158</a>,<a href="#ref-159">159</a></sup>. In addition, tigecycline has carried a black box warning since 2013 for increased all-cause mortality, observed during an FDA meta-analysis evaluating tigecycline across all indications, noted in patients treated for ventilator-associated pneumonia<sup><a href="#ref-157">157</a></sup>. In small clinical trials evaluating tigecycline for complicated intra-abdominal infections and SSTI, it demonstrated similar efficacy relative to comparators (imipenem/cilastatin and vancomycin with aztreonam for each indication, respectively) in patients with concomitant bacteremia; however, no cases of VREB were reported in these studies<sup><a href="#ref-160">160</a>,<a href="#ref-161">161</a></sup>. Although tigecycline may be useful in patients with difficult-to-treat infections who have no superior treatment alternatives, it is lacking in clinical data to support its use for VRE infections, especially for VREB.</p></div><div class=section><a name=d21151e3231 class=n-a></a><h3 class=section-title>Antibiotic combinations<sup><a href="#ref-162">162</a></sup></h3><p class="" id=d21151e3238><b><i>Daptomycin plus β-lactams</i>.</b> The synergy of several β-lactam antibiotics in combination with daptomycin against VRE has been evaluated <i>in vitro</i>. The mechanism by which this occurs is similar to that described in cases of methicillin-resistant <i>Staphylococcus aureus</i><sup><a href="#ref-162">162</a>,<a href="#ref-163">163</a></sup>, although resistance mechanisms for <i>enterococci</i> are more complex. In the presence of β-lactams, the charge of the bacterial surface becomes more negative, which facilitates binding of the daptomycin-calcium complex, even in cases of non-susceptibility to daptomycin. This leads to enhanced membrane depolarization, increased fluidity, and susceptibility to killing by cationic calcium-daptomycin and a diverse range of human cationic antimicrobial peptides, notably cathelicidin LL-37<sup><a href="#ref-164">164</a>,<a href="#ref-165">165</a></sup>. Synergistic effects have been observed <i>in vitro</i> with ampicillin, ceftriaxone, ceftobiprole, and ceftaroline, even in the presence of resistance to these β-lactams<sup><a href="#ref-164">164</a>–<a href="#ref-167">167</a></sup>. However, when combinations with ampicillin, ceftriaxone, or ceftaroline have been tested against DNS vancomycin-resistant <i>E. faecium</i> strains, it is unclear which β-lactam is preferred. Both ampicillin and ceftaroline have demonstrated superior synergism in separate studies from the same group<sup><a href="#ref-164">164</a>–<a href="#ref-168">168</a></sup>. More recent studies have shown that, compared to other β-lactams, ertapenem may have more synergistic activity, especially for DNS VRE strains<sup><a href="#ref-169">169</a>,<a href="#ref-170">170</a></sup>.</p><p class="" id=d21151e3295>Based on these data, combination treatment has been explored with anecdotal reports of success. Sakoulas <i>et al</i>. reported a case of a hemodialysis patient with ampicillin-resistant vancomycin-resistant <i>E. faecium</i> infective endocarditis failing seven days of therapy with daptomycin plus linezolid despite susceptibility to each<sup><a href="#ref-164">164</a></sup>. Treatment with high-dose daptomycin (12 mg/kg) plus ampicillin 1,000 mg every six hours resulted in blood culture clearance within 24 hours. The authors also noted that, with ampicillin, daptomycin MICs decreased from 1.0 to 0.38 mg/L. This combination was also successful in an 89-year-old female treated for six weeks for <i>E. faecalis</i> infective endocarditis susceptible to both ampicillin and daptomycin<sup><a href="#ref-171">171</a></sup>. Combined with ceftaroline at a dose of 600 mg every eight hours, daptomycin (at 8 mg/kg dosing) was successfully used to treat a 63-year-old man with E. faecalis endocarditis unresponsive to other therapies<sup><a href="#ref-172">172</a></sup>. In contrast, the combination of ceftriaxone and daptomycin failed in a case of <i>E. faecalis</i> endocarditis<sup><a href="#ref-173">173</a></sup>.</p><p class="" id=d21151e3327><b><i>Daptomycin plus fosfomycin</i>.</b> Several studies have examined the synergy between daptomycin combined with intravenous fosfomycin. In two time-kill assays, the combination displayed bactericidal activity against all strains of VRE with greater killing effect than monotherapy<sup><a href="#ref-174">174</a></sup> and was more potent than combinations of daptomycin with ampicillin or linezolid<sup><a href="#ref-175">175</a></sup>. In 72-hour <i>in vitro</i> PK/PD models, the addition of fosfomycin to both 8 and 12 mg/kg/day of daptomycin resulted in significantly greater bactericidal activity than daptomycin alone against all daptomycin-susceptible (DS) isolates and prevented the development of daptomycin resistance in two out of three of these isolates. However, the higher daptomycin dose of 12 mg/kg/day was necessary to maintain bactericidal activity for the entire 72 hours. No synergy was observed against DNS strains<sup><a href="#ref-176">176</a></sup>. The only <i>in vivo</i> data available on this combination come from rat models of vancomycin-resistant <i>E. faecalis</i> endocarditis with high-level gentamicin resistance, in which sterilization of valves was achieved more frequently with the combination therapy (<i>P</i> = 0.3)<sup><a href="#ref-177">177</a></sup>. However, it is worth noting that an intravenous formulation of fosfomycin is not available in the US, although it is currently in late-stage clinical trials (<a href="#T2">Table 2</a>).</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Key points.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21151e3377 class=n-a></a><tbody><a name=d21151e3379 class=n-a></a><tr><a name=d21151e3381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21151e3383 class=n-a></a>• Vancomycin-resistant enterococci (VRE) colonization is, at many centers, common and increasing in frequency.<br class=br>• VRE colonization surveillance is not a standard practice at all centers but is recommended in the presence of ongoing strain transmission.<br class=br>• Patients colonized with VRE, especially with its dominance in the intestinal microbiome, have a high rate of development of VRE bacteremia (VREB), and this is most likely to occur during receipt of broad-spectrum antibiotics.<br class=br>• VREB is associated with excess mortality, but attributable mortality appears to be limited, indicating that it may be a surrogate marker of mortality, which is more related to the presence of comorbidities.<br class=br>• While the presence of colonization is a predictor of risk of VREB, there is no evidence that therapy directed at VRE in patients with persisting fever and negative cultures improves outcomes.<br class=br>• Daptomycin and linezolid are the current mainstays of therapy for VREB; emergence of isolates with reduced susceptibility to both agents may pose future challenges to treatment <br class=br>• In patients with persisting bacteremia despite appropriate monotherapy, a combination of daptomycin with a β-lactam antibiotic, such as ampicillin, can be considered.</td></tr></tbody></table></div><p class="" id=d21151e3403><b><i>Daptomycin plus tigecycline</i>.</b> Although monotherapy with tigecycline is not recommended, its combination with daptomycin has been associated with favorable outcomes in several case reports<sup><a href="#ref-178">178</a>–<a href="#ref-181">181</a></sup>. The first case report was of a 62-year-old male with infective endocarditis due to <i>E. faecium</i> resistant to ampicillin, chloramphenicol, linezolid, vancomycin, and quinupristin/dalfopristin and lacked both gentamicin and streptomycin synergy<sup><a href="#ref-178">178</a></sup>. Sterilization of the bloodstream was achieved within three days of starting daptomycin and tigecycline. Similarly, a 39-year-old female with VRE endocarditis—<i>E. faecium</i> resistant to linezolid and with a daptomycin MIC of 4 mcg/mL—failed treatment with daptomycin at 8 mg/kg/day dosing<sup><a href="#ref-179">179</a></sup>. Microbiological cure was achieved with the addition of tigecycline, and blood cultures remained negative nine weeks after discharge. Jaspan <i>et al</i>. reported a case of a 21-month-old female with refractory acute biphenotypic leukemia who developed VREB<sup><a href="#ref-180">180</a></sup>. She was treated with linezolid plus daptomycin with resultant bloodstream sterilization but continued to be febrile and eventually her cerebrospinal fluid (CSF) grew a linezolid-resistant VRE strain. Treatment with intravenous and intraventricular daptomycin plus tigecycline resulted in sterilization of the CSF after 48 hours.</p><p class="" id=d21151e3440><b><i>Linezolid combinations</i>.</b> Gentamicin, rifampin, and doxycycline have displayed potential benefit when used with linezolid, but evidence supporting linezolid combinations is sporadic and contradictory<sup><a href="#ref-182">182</a>–<a href="#ref-185">185</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e3458>Conclusions</h2><p class="" id=d21151e3461>VRE has become a major cause of bacteremia in HSCT recipients. Although VRE infection does not significantly increase mortality in this population, it has important implications in HSCT outcomes. Colonization, as a precondition to VRE invasive disease, can be used to identify patients at high risk of bacteremia. Further studies are needed to examine the utility and impact of routine stool screening—especially with PCR—and isolation of colonized patients. How best to utilize data obtained from surveillance cultures remains a controversy in clinical practice. In centers with high rates of colonization and progression to VREB, empiric anti-VRE therapy may be warranted when antibiotics against GP bacteria are necessary. Further investigation is warranted to establish a more precise algorithm for indications of empirical VRE-active therapy in febrile HSCT recipients, incorporating factors such as colonization status, antimicrobial exposures, and patient/treatment factors. Targeted therapy against VRE continues to be centered in the use of daptomycin and linezolid. Despite the advent of new agents with excellent <i>in vitro</i> activity against VRE and theoretical benefit of antibiotic combinations, clinical data supporting their use for invasive VRE infections are still lacking. In patients with persisting bacteremia despite appropriate monotherapy, a combination of daptomycin with a β-lactam antibiotic, such as ampicillin, can be considered.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21151e3468>Search criteria</h2><p class="" id=d21151e3471>"VRE" [tw] OR "vancomycin resistant enterococcus" [tw] AND "stem cell" [tw] - 56</p><p class="" id=d21151e3474><i>"VRE"[tw] OR "vancomycin resistant enterococcus"[tw] AND ("stem cell"[tw] OR "bone marrow*"[tw]) – 84</i></p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d21151e1 class=n-a></a><h2 class=main-title id=d21761>Competing interests</h2><p class=metadata-entry><a name=d21151e99 class=n-a></a><p id=d21151e100> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d21151e1 class=n-a></a><h2 class=main-title id=d21763>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d21151e3482 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d22372>References</h2><div class="section ref-list"><a name=d21151e3482 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d21151e3489 class=n-a></a>Leclercq R, Derlot E, Duval J, <i> et al.</i>: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. <i>N Engl J Med.</i> 1988; <b>319</b>(3): 157–61. <a target=xrefwindow id=d21151e3500 href="http://www.ncbi.nlm.nih.gov/pubmed/2968517">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3503 href="http://dx.doi.org/10.1056/NEJM198807213190307">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d21151e3512 class=n-a></a>Hidron AI, Edwards JR, Patel J, <i> et al.</i>: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. <i>Infect Control Hosp Epidemiol.</i> 2008; <b>29</b>(11): 996–1011. <a target=xrefwindow id=d21151e3523 href="http://www.ncbi.nlm.nih.gov/pubmed/18947320">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3526 href="http://dx.doi.org/10.1086/591861">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726696741"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e3535 class=n-a></a>Weiner LM, Webb AK, Limbago B, <i> et al.</i>: Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. <i>Infect Control Hosp Epidemiol.</i> 2016; <b>37</b>(11): 1288–301. <a target=xrefwindow id=d21151e3546 href="http://www.ncbi.nlm.nih.gov/pubmed/27573805">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3549 href="http://dx.doi.org/10.1017/ice.2016.174">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726696741">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d21151e3562 class=n-a></a>Centers for Disease Control and Prevention: Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA [Internet]. 2013. <a target=xrefwindow id=d21151e3564 href="http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d21151e3573 class=n-a></a>Matar MJ, Tarrand J, Raad I, <i> et al.</i>: Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. <i>Am J Infect Control.</i> 2006; <b>34</b>(8): 534–6. <a target=xrefwindow id=d21151e3584 href="http://www.ncbi.nlm.nih.gov/pubmed/17015161">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3587 href="http://dx.doi.org/10.1016/j.ajic.2006.04.205">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d21151e3597 class=n-a></a>Tavadze M, Rybicki L, Mossad S, <i> et al.</i>: Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplant.</i> 2014; <b>49</b>(10): 1310–6. <a target=xrefwindow id=d21151e3608 href="http://www.ncbi.nlm.nih.gov/pubmed/25111516">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3611 href="http://dx.doi.org/10.1038/bmt.2014.150">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d21151e3620 class=n-a></a>Kamboj M, Chung D, Seo SK, <i> et al.</i>: The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. <i>Biol Blood Marrow Transplant.</i> 2010; <b>16</b>(11): 1576–81. <a target=xrefwindow id=d21151e3631 href="http://www.ncbi.nlm.nih.gov/pubmed/20685257">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3634 href="http://dx.doi.org/10.1016/j.bbmt.2010.05.008">Publisher Full Text </a> | <a target=xrefwindow id=d21151e3638 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3670412">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727038383"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e3647 class=n-a></a>Ford CD, Gazdik MA, Lopansri BK, <i> et al.</i>: Vancomycin-Resistant <i>Enterococcus</i> Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes. <i>Biol Blood Marrow Transplant.</i> 2017; <b>23</b>(2): 340–6. <a target=xrefwindow id=d21151e3661 href="http://www.ncbi.nlm.nih.gov/pubmed/27890428">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3665 href="http://dx.doi.org/10.1016/j.bbmt.2016.11.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727038383">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d21151e3678 class=n-a></a>Hefazi M, Damlaj M, Alkhateeb HB, <i> et al.</i>: Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transpl Infect Dis.</i> 2016; <b>18</b>(6): 913–20. <a target=xrefwindow id=d21151e3692 href="http://www.ncbi.nlm.nih.gov/pubmed/27642723">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3696 href="http://dx.doi.org/10.1111/tid.12612">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d21151e3705 class=n-a></a>Kang Y, Vicente M, Parsad S, <i> et al.</i>: Evaluation of risk factors for vancomycin-resistant <i>Enterococcus</i> bacteremia among previously colonized hematopoietic stem cell transplant patients. <i>Transpl Infect Dis.</i> 2013; <b>15</b>(5): 466–73. <a target=xrefwindow id=d21151e3719 href="http://www.ncbi.nlm.nih.gov/pubmed/23911080">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3723 href="http://dx.doi.org/10.1111/tid.12120">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d21151e3732 class=n-a></a>Almyroudis NG, Fuller A, Jakubowski A, <i> et al.</i>: Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. <i>Transpl Infect Dis.</i> 2005; <b>7</b>(1): 11–7. <a target=xrefwindow id=d21151e3743 href="http://www.ncbi.nlm.nih.gov/pubmed/15984943">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3746 href="http://dx.doi.org/10.1111/j.1399-3062.2005.00088.x">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d21151e3756 class=n-a></a>Weinstock DM, Conlon M, Iovino C, <i> et al.</i>: Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. <i>Biol Blood Marrow Transplant.</i> 2007; <b>13</b>(5): 615–21. <a target=xrefwindow id=d21151e3767 href="http://www.ncbi.nlm.nih.gov/pubmed/17448922">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3770 href="http://dx.doi.org/10.1016/j.bbmt.2007.01.078">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d21151e3779 class=n-a></a>Satlin MJ, Soave R, Racanelli AC, <i> et al.</i>: The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. <i>Leuk Lymphoma.</i> 2014; <b>55</b>(12): 2858–65. <a target=xrefwindow id=d21151e3790 href="http://www.ncbi.nlm.nih.gov/pubmed/24559288">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3793 href="http://dx.doi.org/10.3109/10428194.2014.896007">Publisher Full Text </a> | <a target=xrefwindow id=d21151e3797 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4316723">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d21151e3806 class=n-a></a>Arias CA, Murray BE: The rise of the <i>Enterococcus</i>: beyond vancomycin resistance. <i>Nat Rev Microbiol.</i> 2012; <b>10</b>(4): 266–78. <a target=xrefwindow id=d21151e3817 href="http://www.ncbi.nlm.nih.gov/pubmed/22421879">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3820 href="http://dx.doi.org/10.1038/nrmicro2761">Publisher Full Text </a> | <a target=xrefwindow id=d21151e3824 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3621121">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d21151e3833 class=n-a></a>Avery R, Kalaycio M, Pohlman B, <i> et al.</i>: Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. <i>Bone Marrow Transplant.</i> 2005; <b>35</b>(5): 497–9. <a target=xrefwindow id=d21151e3844 href="http://www.ncbi.nlm.nih.gov/pubmed/15640812">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3847 href="http://dx.doi.org/10.1038/sj.bmt.1704821">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d21151e3856 class=n-a></a>Kapur D, Dorsky D, Feingold JM, <i> et al.</i>: Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplant.</i> 2000; <b>25</b>(2): 147–52. <a target=xrefwindow id=d21151e3867 href="http://www.ncbi.nlm.nih.gov/pubmed/10673672">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3870 href="http://dx.doi.org/10.1038/sj.bmt.1702123">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d21151e3879 class=n-a></a>Zirakzadeh A, Gastineau DA, Mandrekar JN, <i> et al.</i>: Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplant.</i> 2008; <b>41</b>(4): 385–92. <a target=xrefwindow id=d21151e3890 href="http://www.ncbi.nlm.nih.gov/pubmed/18084341">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3893 href="http://dx.doi.org/10.1038/sj.bmt.1705912">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d21151e3903 class=n-a></a>Vydra J, Shanley RM, George I, <i> et al.</i>: Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. <i>Clin Infect Dis.</i> 2012; <b>55</b>(6): 764–70. <a target=xrefwindow id=d21151e3914 href="http://www.ncbi.nlm.nih.gov/pubmed/22693346">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3917 href="http://dx.doi.org/10.1093/cid/cis550">Publisher Full Text </a> | <a target=xrefwindow id=d21151e3921 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3657510">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d21151e3930 class=n-a></a>Rolston KV, Jiang Y, Matar M: VRE fecal colonization/infection in cancer patients. <i>Bone Marrow Transplant.</i> 2007; <b>39</b>(9): 567–8. <a target=xrefwindow id=d21151e3938 href="http://www.ncbi.nlm.nih.gov/pubmed/17351646">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3941 href="http://dx.doi.org/10.1038/sj.bmt.1705639">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d21151e3950 class=n-a></a>Wang JS, Muzevich K, Edmond MB, <i> et al.</i>: Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature. <i>Int J Infect Dis.</i> 2014; <b>25</b>: 26–31. <a target=xrefwindow id=d21151e3961 href="http://www.ncbi.nlm.nih.gov/pubmed/24846601">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3964 href="http://dx.doi.org/10.1016/j.ijid.2014.01.009">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d21151e3973 class=n-a></a>Frasca KL, Schuster MG: Vancomycin-resistant enterococcal meningitis in an autologous stem cell transplant recipient cured with linezolid. <i>Transpl Infect Dis.</i> 2013; <b>15</b>(1): E1–4. <a target=xrefwindow id=d21151e3981 href="http://www.ncbi.nlm.nih.gov/pubmed/23173835">PubMed Abstract </a> | <a target=xrefwindow id=d21151e3984 href="http://dx.doi.org/10.1111/tid.12032">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d21151e3993 class=n-a></a>Worth LJ, Thursky KA, Seymour JF, <i> et al.</i>: Vancomycin-resistant <i>Enterococcus faecium</i> infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. <i>Eur J Haematol.</i> 2007; <b>79</b>(3): 226–33. <a target=xrefwindow id=d21151e4007 href="http://www.ncbi.nlm.nih.gov/pubmed/17655696">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4011 href="http://dx.doi.org/10.1111/j.1600-0609.2007.00911.x">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d21151e4020 class=n-a></a>Dubberke ER, Hollands JM, Georgantopoulos P, <i> et al.</i>: Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? <i>Bone Marrow Transplant.</i> 2006; <b>38</b>(12): 813–9. <a target=xrefwindow id=d21151e4031 href="http://www.ncbi.nlm.nih.gov/pubmed/17057724">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4034 href="http://dx.doi.org/10.1038/sj.bmt.1705530">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d21151e4044 class=n-a></a>DiazGranados CA, Jernigan JA: Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. <i>J Infect Dis.</i> 2005; <b>191</b>(4): 588–95. <a target=xrefwindow id=d21151e4052 href="http://www.ncbi.nlm.nih.gov/pubmed/15655783">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4055 href="http://dx.doi.org/10.1086/427512">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d21151e4064 class=n-a></a>Cho SY, Lee DG, Choi SM, <i> et al.</i>: Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. <i>BMC Infect Dis.</i> 2013; <b>13</b>: 504. <a target=xrefwindow id=d21151e4075 href="http://www.ncbi.nlm.nih.gov/pubmed/24164924">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4078 href="http://dx.doi.org/10.1186/1471-2334-13-504">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4082 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3870976">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d21151e4091 class=n-a></a>Salgado CD, Ison MG: Should clinicians worry about vancomycin-resistant <i>Enterococcus</i> bloodstream infections? <i>Bone Marrow Transplant.</i> 2006; <b>38</b>(12): 771–4. <a target=xrefwindow id=d21151e4102 href="http://www.ncbi.nlm.nih.gov/pubmed/17133239">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4105 href="http://dx.doi.org/10.1038/sj.bmt.1705532">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727761899"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4114 class=n-a></a>Ford CD, Lopansri BK, Gazdik MA, <i> et al.</i>: The clinical impact of vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection in patients undergoing autologous transplantation. <i>Transpl Infect Dis.</i> 2015; <b>17</b>(5): 688–94. <a target=xrefwindow id=d21151e4128 href="http://www.ncbi.nlm.nih.gov/pubmed/26256692">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4132 href="http://dx.doi.org/10.1111/tid.12433">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727761899">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d21151e4145 class=n-a></a>Li L, Soave R, Small C, <i> et al.</i>: Colonization with Vancomycin-Resistant Enterococci and Subsequent Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infect Dis.</i> 2016; <b>3</b>(suppl_1): 2322. <a target=xrefwindow id=d21151e4156 href="http://dx.doi.org/10.1093/ofid/ofw172.1869">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d21151e4165 class=n-a></a>Almyroudis NG, Lesse AJ, Hahn T, <i> et al.</i>: Molecular epidemiology and risk factors for colonization by vancomycin-resistant <i>Enterococcus</i> in patients with hematologic malignancies. <i>Infect Control Hosp Epidemiol.</i> 2011; <b>32</b>(5): 490–6. <a target=xrefwindow id=d21151e4179 href="http://www.ncbi.nlm.nih.gov/pubmed/21515980">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4183 href="http://dx.doi.org/10.1086/659408">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d21151e4193 class=n-a></a>Suntharam N, Lankford MG, Trick WE, <i> et al.</i>: Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. <i>Diagn Microbiol Infect Dis.</i> 2002; <b>43</b>(3): 183–8. <a target=xrefwindow id=d21151e4204 href="http://www.ncbi.nlm.nih.gov/pubmed/12106950">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4207 href="http://dx.doi.org/10.1016/S0732-8893(02)00392-9">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d21151e4216 class=n-a></a>Kaveh M, Bazargani A, Ramzi M, <i> et al.</i>: Colonization Rate and Risk Factors of Vancomycin-Resistant Enterococci among Patients Received Hematopoietic Stem Cell Transplantation in Shiraz, Southern Iran. <i>Int J Organ Transplant Med.</i> 2016; <b>7</b>(4): 197–205. <a target=xrefwindow id=d21151e4227 href="http://www.ncbi.nlm.nih.gov/pubmed/28078058">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5219580">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1025800"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4239 class=n-a></a>Eckburg PB, Bik EM, Bernstein CN, <i> et al.</i>: Diversity of the human intestinal microbial flora. <i>Science.</i> 2005; <b>308</b>(5728): 1635–8. <a target=xrefwindow id=d21151e4250 href="http://www.ncbi.nlm.nih.gov/pubmed/15831718">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4253 href="http://dx.doi.org/10.1126/science.1110591">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1395357">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1025800">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1124158"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4270 class=n-a></a>Brandl K, Plitas G, Mihu CN, <i> et al.</i>: Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. <i>Nature.</i> 2008; <b>455</b>(7214): 804–7. <a target=xrefwindow id=d21151e4281 href="http://www.ncbi.nlm.nih.gov/pubmed/18724361">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4284 href="http://dx.doi.org/10.1038/nature07250">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4288 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2663337">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1124158">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2815960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4301 class=n-a></a>Kinnebrew MA, Ubeda C, Zenewicz LA, <i> et al.</i>: Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant <i>Enterococcus</i> infection. <i>J Infect Dis.</i> 2010; <b>201</b>(4): 534–43. <a target=xrefwindow id=d21151e4315 href="http://www.ncbi.nlm.nih.gov/pubmed/20064069">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4319 href="http://dx.doi.org/10.1086/650203">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2811237">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2815960">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9602956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4335 class=n-a></a>Ubeda C, Taur Y, Jenq RR, <i> et al.</i>: Vancomycin-resistant <i>Enterococcus</i> domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. <i>J Clin Invest.</i> 2010; <b>120</b>(12): 4332–41. <a target=xrefwindow id=d21151e4349 href="http://www.ncbi.nlm.nih.gov/pubmed/21099116">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4353 href="http://dx.doi.org/10.1172/JCI43918">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4356 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2993598">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9602956">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d21151e4370 class=n-a></a>Taur Y, Xavier JB, Lipuma L, <i> et al.</i>: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Clin Infect Dis.</i> 2012; <b>55</b>(7): 905–14. <a target=xrefwindow id=d21151e4381 href="http://www.ncbi.nlm.nih.gov/pubmed/22718773">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4384 href="http://dx.doi.org/10.1093/cid/cis580">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3657523">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d21151e4397 class=n-a></a>Al-Nassir WN, Sethi AK, Li Y, <i> et al.</i>: Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of <i>Clostridium difficile</i>-associated disease. <i>Antimicrob Agents Chemother.</i> 2008; <b>52</b>(7): 2403–6. <a target=xrefwindow id=d21151e4411 href="http://www.ncbi.nlm.nih.gov/pubmed/18443120">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4415 href="http://dx.doi.org/10.1128/AAC.00090-08">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2443881">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d21151e4427 class=n-a></a>Gerding DN: Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? <i>Clin Infect Dis.</i> 1997; <b>25 Suppl 2</b>: S206–10. <a target=xrefwindow id=d21151e4435 href="http://www.ncbi.nlm.nih.gov/pubmed/9310680">PubMed Abstract </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d21151e4444 class=n-a></a>Fujitani S, George WL, Morgan MA, <i> et al.</i>: Implications for vancomycin-resistant Enterococcus colonization associated with <i>Clostridium difficile</i> infections. <i>Am J Infect Control.</i> 2011; <b>39</b>(3): 188–93. <a target=xrefwindow id=d21151e4458 href="http://www.ncbi.nlm.nih.gov/pubmed/21458682">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4462 href="http://dx.doi.org/10.1016/j.ajic.2010.10.024">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d21151e4471 class=n-a></a>Matar MJ, Safdar A, Rolston KV: Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. <i>Clin Infect Dis.</i> 2006; <b>42</b>(10): 1506–7. <a target=xrefwindow id=d21151e4479 href="http://www.ncbi.nlm.nih.gov/pubmed/16619176">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4482 href="http://dx.doi.org/10.1086/503675">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d21151e4491 class=n-a></a>Sloan LM, Uhl JR, Vetter EA, <i> et al.</i>: Comparison of the Roche LightCycler <i>vanA/vanB</i> detection assay and culture for detection of vancomycin-resistant enterococci from perianal swabs. <i>J Clin Microbiol.</i> 2004; <b>42</b>(6): 2636–43. <a target=xrefwindow id=d21151e4505 href="http://www.ncbi.nlm.nih.gov/pubmed/15184445">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4509 href="http://dx.doi.org/10.1128/JCM.42.6.2636-2643.2004">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4512 href="http://www.ncbi.nlm.nih.gov/pmc/articles/427841">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d21151e4522 class=n-a></a>Bourdon N, Bérenger R, Lepoultier R, <i> et al.</i>: Rapid detection of vancomycin-resistant enterococci from rectal swabs by the Cepheid Xpert <i>vanA/vanB</i> assay. <i>Diagn Microbiol Infect Dis.</i> 2010; <b>67</b>(3): 291–3. <a target=xrefwindow id=d21151e4536 href="http://www.ncbi.nlm.nih.gov/pubmed/20542208">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4540 href="http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.009">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d21151e4549 class=n-a></a>Devrim F, Gülfidan G, Gözmen S, <i> et al.</i>: Comparison of the BD GeneOhm VanR assay and a chromogenic agar-based culture method in screening for vancomycin-resistant enterococci in rectal specimens of pediatric hematology-oncology patients. <i>Turk J Pediatr.</i> 2015; <b>57</b>(2): 161–6. <a target=xrefwindow id=d21151e4560 href="http://www.ncbi.nlm.nih.gov/pubmed/26690597">PubMed Abstract </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d21151e4569 class=n-a></a>Papadimitriou-Olivgeris M, Filippidou S, Kolonitsiou F, <i> et al.</i>: Pitfalls in the identification of <i>Enterococcus</i> species and the detection of <i>vanA</i> and <i>vanB</i> genes. <i>Lett Appl Microbiol.</i> 2016; <b>63</b>(3): 189–95. <a target=xrefwindow id=d21151e4590 href="http://www.ncbi.nlm.nih.gov/pubmed/27367648">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4593 href="http://dx.doi.org/10.1111/lam.12610">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d21151e4602 class=n-a></a>Usacheva EA, Ginocchio CC, Morgan M, <i> et al.</i>: Prospective, multicenter evaluation of the BD GeneOhm VanR assay for direct, rapid detection of vancomycin-resistant <i>Enterococcus</i> species in perianal and rectal specimens. <i>Am J Clin Pathol.</i> 2010; <b>134</b>(2): 219–26. <a target=xrefwindow id=d21151e4616 href="http://www.ncbi.nlm.nih.gov/pubmed/20660324">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4620 href="http://dx.doi.org/10.1309/AJCPR1K0QFLBJSNH">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732318229"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4629 class=n-a></a>Holzknecht BJ, Hansen DS, Nielsen L, <i> et al.</i>: Screening for vancomycin-resistant enterococci with Xpert® <i>vanA/vanB</i>: diagnostic accuracy and impact on infection control decision making. <i>New Microbes New Infect.</i> 2017; <b>16</b>: 54–9. <a target=xrefwindow id=d21151e4643 href="http://www.ncbi.nlm.nih.gov/pubmed/28203378">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4647 href="http://dx.doi.org/10.1016/j.nmni.2016.12.020">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5295639">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732318229">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d21151e4663 class=n-a></a>Edmond MB, Ober JF, Weinbaum DL, <i> et al.</i>: Vancomycin-resistant <i>Enterococcus faecium</i> bacteremia: risk factors for infection. <i>Clin Infect Dis.</i> 1995; <b>20</b>(5): 1126–33. <a target=xrefwindow id=d21151e4677 href="http://www.ncbi.nlm.nih.gov/pubmed/7619987">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4681 href="http://dx.doi.org/10.1093/clinids/20.5.1126">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d21151e4691 class=n-a></a>Donskey CJ, Chowdhry TK, Hecker MT, <i> et al.</i>: Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. <i>N Engl J Med.</i> 2000; <b>343</b>(26): 1925–32. <a target=xrefwindow id=d21151e4702 href="http://www.ncbi.nlm.nih.gov/pubmed/11136263">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4705 href="http://dx.doi.org/10.1056/NEJM200012283432604">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4370337">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d21151e4718 class=n-a></a>Carmeli Y, Eliopoulos GM, Samore MH: Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant <i>Enterococcus</i>. <i>Emerging Infect Dis.</i> 2002; <b>8</b>(8): 802–7. <a target=xrefwindow id=d21151e4729 href="http://www.ncbi.nlm.nih.gov/pubmed/12141965">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2732508">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d21151e4741 class=n-a></a>Fridkin SK, Edwards JR, Courval JM, <i> et al.</i>: The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. <i>Ann Intern Med.</i> 2001; <b>135</b>(3): 175–83. <a target=xrefwindow id=d21151e4752 href="http://www.ncbi.nlm.nih.gov/pubmed/11487484">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4755 href="http://dx.doi.org/10.7326/0003-4819-135-3-200108070-00009">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d21151e4764 class=n-a></a>Morris JG Jr, Shay DK, Hebden JN, <i> et al.</i>: Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. <i>Ann Intern Med.</i> 1995; <b>123</b>(4): 250–9. <a target=xrefwindow id=d21151e4775 href="http://www.ncbi.nlm.nih.gov/pubmed/7611590">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4778 href="http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00002">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d21151e4787 class=n-a></a>Taur Y, Jenq RR, Ubeda C, <i> et al.</i>: Role of intestinal microbiota in transplantation outcomes. <i>Best Pract Res Clin Haematol.</i> 2015; <b>28</b>(2–3): 155–61. <a target=xrefwindow id=d21151e4798 href="http://www.ncbi.nlm.nih.gov/pubmed/26590773">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4801 href="http://dx.doi.org/10.1016/j.beha.2015.10.013">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4805 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4656136">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d21151e4814 class=n-a></a>Chung H, Kasper DL: Microbiota-stimulated immune mechanisms to maintain gut homeostasis. <i>Curr Opin Immunol.</i> 2010; <b>22</b>(4): 455–60. <a target=xrefwindow id=d21151e4822 href="http://www.ncbi.nlm.nih.gov/pubmed/20656465">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4825 href="http://dx.doi.org/10.1016/j.coi.2010.06.008">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716497873"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4835 class=n-a></a>Eriguchi Y, Takashima S, Oka H, <i> et al.</i>: Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. <i>Blood.</i> 2012; <b>120</b>(1): 223–31. <a target=xrefwindow id=d21151e4846 href="http://www.ncbi.nlm.nih.gov/pubmed/22535662">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4849 href="http://dx.doi.org/10.1182/blood-2011-12-401166">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716497873">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d21151e4862 class=n-a></a>Serody J: Bacterial sepsis and GI tract GVHD: more commensal than you think. <i>Blood.</i> 2012; <b>120</b>(1): 6–7. <a target=xrefwindow id=d21151e4870 href="http://www.ncbi.nlm.nih.gov/pubmed/22767576">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4873 href="http://dx.doi.org/10.1182/blood-2012-05-427435">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d21151e4882 class=n-a></a>Holler E, Butzhammer P, Schmid K, <i> et al.</i>: Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(5): 640–5. <a target=xrefwindow id=d21151e4893 href="http://www.ncbi.nlm.nih.gov/pubmed/24492144">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4896 href="http://dx.doi.org/10.1016/j.bbmt.2014.01.030">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4973578">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471123"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e4909 class=n-a></a>Webb BJ, Healy R, Majers J, <i> et al.</i>: Prediction of Bloodstream Infection Due to Vancomycin-Resistant Enterococcus in Patients Undergoing Leukemia Induction or Hematopoietic Stem-Cell Transplantation. <i>Clin Infect Dis.</i> 2017; <b>64</b>(12): 1753–9. <a target=xrefwindow id=d21151e4920 href="http://www.ncbi.nlm.nih.gov/pubmed/28369204">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4923 href="http://dx.doi.org/10.1093/cid/cix232">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471123">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d21151e4936 class=n-a></a>Taur Y, Jenq RR, Perales MA, <i> et al.</i>: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood.</i> 2014; <b>124</b>(7): 1174–82. <a target=xrefwindow id=d21151e4947 href="http://www.ncbi.nlm.nih.gov/pubmed/24939656">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4950 href="http://dx.doi.org/10.1182/blood-2014-02-554725">Publisher Full Text </a> | <a target=xrefwindow id=d21151e4954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4133489">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d21151e4963 class=n-a></a>Muto CA, Jernigan JA, Ostrowsky BE, <i> et al.</i>: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. <i>Infect Control Hosp Epidemiol.</i> 2003; <b>24</b>(5): 362–86. <a target=xrefwindow id=d21151e4974 href="http://www.ncbi.nlm.nih.gov/pubmed/12785411">PubMed Abstract </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d21151e4984 class=n-a></a>Hicheri Y, Einsele H, Martino R, <i> et al.</i>: Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Transpl Infect Dis.</i> 2013; <b>15</b>(3): 251–8. <a target=xrefwindow id=d21151e4995 href="http://www.ncbi.nlm.nih.gov/pubmed/23465046">PubMed Abstract </a> | <a target=xrefwindow id=d21151e4998 href="http://dx.doi.org/10.1111/tid.12064">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d21151e5007 class=n-a></a>Venkatesh AK, Lankford MG, Rooney DM, <i> et al.</i>: Use of electronic alerts to enhance hand hygiene compliance and decrease transmission of vancomycin-resistant <i>Enterococcus</i> in a hematology unit. <i>Am J Infect Control.</i> 2008; <b>36</b>(3): 199–205. <a target=xrefwindow id=d21151e5021 href="http://www.ncbi.nlm.nih.gov/pubmed/18371516">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5025 href="http://dx.doi.org/10.1016/j.ajic.2007.11.005">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d21151e5034 class=n-a></a>Sodré da Costa LS, Neves VM, Marra AR, <i> et al.</i>: Measuring hand hygiene compliance in a hematology-oncology unit: a comparative study of methodologies. <i>Am J Infect Control.</i> 2013; <b>41</b>(11): 997–1000. <a target=xrefwindow id=d21151e5045 href="http://www.ncbi.nlm.nih.gov/pubmed/23769833">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5048 href="http://dx.doi.org/10.1016/j.ajic.2013.03.301">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d21151e5057 class=n-a></a>Grabsch EA, Mahony AA, Cameron DR, <i> et al.</i>: Significant reduction in vancomycin-resistant enterococcus colonization and bacteraemia after introduction of a bleach-based cleaning-disinfection programme. <i>J Hosp Infect.</i> 2012; <b>82</b>(4): 234–42. <a target=xrefwindow id=d21151e5068 href="http://www.ncbi.nlm.nih.gov/pubmed/23103245">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5071 href="http://dx.doi.org/10.1016/j.jhin.2012.08.010">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d21151e5080 class=n-a></a>Vernon MO, Hayden MK, Trick WE, <i> et al.</i>: Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. <i>Arch Intern Med.</i> 2006; <b>166</b>(3): 306–12. <a target=xrefwindow id=d21151e5091 href="http://www.ncbi.nlm.nih.gov/pubmed/16476870">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5094 href="http://dx.doi.org/10.1001/archinte.166.3.306">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1159707"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5103 class=n-a></a>Climo MW, Sepkowitz KA, Zuccotti G, <i> et al.</i>: The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant <i>Staphylococcus aureus</i>, vancomycin-resistant <i>Enterococcus</i>, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. <i>Crit Care Med.</i> 2009; <b>37</b>(6): 1858–65. <a target=xrefwindow id=d21151e5121 href="http://www.ncbi.nlm.nih.gov/pubmed/19384220">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5124 href="http://dx.doi.org/10.1097/CCM.0b013e31819ffe6d">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1159707">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728721949"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5138 class=n-a></a>Kim HY, Lee WK, Na S, <i> et al.</i>: The effects of chlorhexidine gluconate bathing on health care-associated infection in intensive care units: A meta-analysis. <i>J Crit Care.</i> 2016; <b>32</b>: 126–37. <a target=xrefwindow id=d21151e5149 href="http://www.ncbi.nlm.nih.gov/pubmed/26705765">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5152 href="http://dx.doi.org/10.1016/j.jcrc.2015.11.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728721949">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d21151e5165 class=n-a></a>Bass P, Karki S, Rhodes D, <i> et al.</i>: Impact of chlorhexidine-impregnated washcloths on reducing incidence of vancomycin-resistant enterococci colonization in hematology-oncology patients. <i>Am J Infect Control.</i> 2013; <b>41</b>(4): 345–8. <a target=xrefwindow id=d21151e5176 href="http://www.ncbi.nlm.nih.gov/pubmed/22980512">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5179 href="http://dx.doi.org/10.1016/j.ajic.2012.04.324">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717978518"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5188 class=n-a></a>Climo MW, Yokoe DS, Warren DK, <i> et al.</i>: Effect of daily chlorhexidine bathing on hospital-acquired infection. <i>N Engl J Med.</i> 2013; <b>368</b>(6): 533–42. <a target=xrefwindow id=d21151e5199 href="http://www.ncbi.nlm.nih.gov/pubmed/23388005">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5202 href="http://dx.doi.org/10.1056/NEJMoa1113849">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5703051">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717978518">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727019881"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5219 class=n-a></a>Mendes ET, Ranzani OT, Marchi AP, <i> et al.</i>: Chlorhexidine bathing for the prevention of colonization and infection with multidrug-resistant microorganisms in a hematopoietic stem cell transplantation unit over a 9-year period: Impact on chlorhexidine susceptibility. <i>Medicine (Baltimore).</i> 2016; <b>95</b>(46): e5271. <a target=xrefwindow id=d21151e5230 href="http://www.ncbi.nlm.nih.gov/pubmed/27861350">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5233 href="http://dx.doi.org/10.1097/MD.0000000000005271">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5237 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5120907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727019881">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d21151e5250 class=n-a></a>Meyer B, Cookson B: Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? <i>J Hosp Infect.</i> 2010; <b>76</b>(3): 200–5. <a target=xrefwindow id=d21151e5258 href="http://www.ncbi.nlm.nih.gov/pubmed/20638752">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5261 href="http://dx.doi.org/10.1016/j.jhin.2010.05.020">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d21151e5270 class=n-a></a>Otter JA, Cummins M, Ahmad F, <i> et al.</i>: Assessing the biological efficacy and rate of recontamination following hydrogen peroxide vapour decontamination. <i>J Hosp Infect.</i> 2007; <b>67</b>(2): 182–8. <a target=xrefwindow id=d21151e5281 href="http://www.ncbi.nlm.nih.gov/pubmed/17884250">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5284 href="http://dx.doi.org/10.1016/j.jhin.2007.07.019">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d21151e5294 class=n-a></a>Salgado CD, Sepkowitz KA, John JF, <i> et al.</i>: Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit. <i>Infect Control Hosp Epidemiol.</i> 2013; <b>34</b>(5): 479–86. <a target=xrefwindow id=d21151e5305 href="http://www.ncbi.nlm.nih.gov/pubmed/23571364">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5308 href="http://dx.doi.org/10.1086/670207">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d21151e5317 class=n-a></a>Nerandzic MM, Thota P, Sankar C T, <i> et al.</i>: Evaluation of a pulsed xenon ultraviolet disinfection system for reduction of healthcare-associated pathogens in hospital rooms. <i>Infect Control Hosp Epidemiol.</i> 2015; <b>36</b>(2): 192–7. <a target=xrefwindow id=d21151e5328 href="http://www.ncbi.nlm.nih.gov/pubmed/25633002">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5331 href="http://dx.doi.org/10.1017/ice.2014.36">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d21151e5340 class=n-a></a>Tomblyn M, Chiller T, Einsele H, <i> et al.</i>: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant.</i> 2009; <b>15</b>(10): 1143–238. <a target=xrefwindow id=d21151e5351 href="http://www.ncbi.nlm.nih.gov/pubmed/19747629">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5354 href="http://dx.doi.org/10.1016/j.bbmt.2009.06.019">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3103296">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d21151e5367 class=n-a></a>D'Agata EM, Gautam S, Green WK, <i> et al.</i>: High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. <i>Clin Infect Dis.</i> 2002; <b>34</b>(2): 167–72. <a target=xrefwindow id=d21151e5378 href="http://www.ncbi.nlm.nih.gov/pubmed/11740703">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5381 href="http://dx.doi.org/10.1086/338234">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d21151e5390 class=n-a></a>Huskins WC, Huckabee CM, O'Grady NP, <i> et al.</i>: Intervention to reduce transmission of resistant bacteria in intensive care. <i>N Engl J Med.</i> 2011; <b>364</b>(15): 1407–18. <a target=xrefwindow id=d21151e5401 href="http://www.ncbi.nlm.nih.gov/pubmed/21488763">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5404 href="http://dx.doi.org/10.1056/NEJMoa1000373">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5408 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3410743">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1007646"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5417 class=n-a></a>Puzniak LA, Leet T, Mayfield J, <i> et al.</i>: To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. <i>Clin Infect Dis.</i> 2002; <b>35</b>(1): 18–25. <a target=xrefwindow id=d21151e5428 href="http://www.ncbi.nlm.nih.gov/pubmed/12060870">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5431 href="http://dx.doi.org/10.1086/340739">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1007646">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d21151e5445 class=n-a></a>Hachem R, Graviss L, Hanna H, <i> et al.</i>: Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. <i>Infect Control Hosp Epidemiol.</i> 2004; <b>25</b>(5): 391–4. <a target=xrefwindow id=d21151e5456 href="http://www.ncbi.nlm.nih.gov/pubmed/15188844">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5459 href="http://dx.doi.org/10.1086/502411">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d21151e5468 class=n-a></a>Morgan DJ, Pineles L, Shardell M, <i> et al.</i>: The effect of contact precautions on healthcare worker activity in acute care hospitals. <i>Infect Control Hosp Epidemiol.</i> 2013; <b>34</b>(1): 69–73. <a target=xrefwindow id=d21151e5479 href="http://www.ncbi.nlm.nih.gov/pubmed/23221195">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5482 href="http://dx.doi.org/10.1086/668775">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d21151e5491 class=n-a></a>Day HR, Perencevich EN, Harris AD, <i> et al.</i>: Depression, anxiety, and moods of hospitalized patients under contact precautions. <i>Infect Control Hosp Epidemiol.</i> 2013; <b>34</b>(3): 251–8. <a target=xrefwindow id=d21151e5502 href="http://www.ncbi.nlm.nih.gov/pubmed/23388359">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5505 href="http://dx.doi.org/10.1086/669526">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d21151e5514 class=n-a></a>Karki S, Leder K, Cheng AC: Patients under contact precautions have an increased risk of injuries and medication errors: a retrospective cohort study. <i>Infect Control Hosp Epidemiol.</i> 2013; <b>34</b>(10): 1118–20. <a target=xrefwindow id=d21151e5522 href="http://www.ncbi.nlm.nih.gov/pubmed/24018935">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5525 href="http://dx.doi.org/10.1086/673153">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d21151e5534 class=n-a></a>Gandra S, Barysauskas CM, Mack DA, <i> et al.</i>: Impact of contact precautions on falls, pressure ulcers and transmission of MRSA and VRE in hospitalized patients. <i>J Hosp Infect.</i> 2014; <b>88</b>(3): 170–6. <a target=xrefwindow id=d21151e5545 href="http://www.ncbi.nlm.nih.gov/pubmed/25441487">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5548 href="http://dx.doi.org/10.1016/j.jhin.2014.09.003">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718133671"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5557 class=n-a></a>Harris AD, Pineles L, Belton B, <i> et al.</i>: Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. <i>JAMA.</i> 2013; <b>310</b>(15): 1571–80. <a target=xrefwindow id=d21151e5568 href="http://www.ncbi.nlm.nih.gov/pubmed/24097234">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5571 href="http://dx.doi.org/10.1001/jama.2013.277815">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5575 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4026208">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718133671">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d21151e5589 class=n-a></a>Rupp ME, Fitzgerald T, Hayes K, <i> et al.</i>: Effect of Cessation of Contact Isolation for Endemic Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant Enterococci. <i>Infect Control Hosp Epidemiol.</i> 2017; <b>38</b>(8): 1005–7. <a target=xrefwindow id=d21151e5603 href="http://www.ncbi.nlm.nih.gov/pubmed/28592333">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5607 href="http://dx.doi.org/10.1017/ice.2017.122">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d21151e5616 class=n-a></a>Bardossy AC, Alsafadi MY, Starr P, <i> et al.</i>: Evaluation of contact precautions for methicillin-resistant <i>Staphylococcus aureus</i> and vancomycin-resistant <i>Enterococcus</i>. <i>Am J Infect Control.</i> 2017; <b>45</b>(12):1369–1371. <a target=xrefwindow id=d21151e5634 href="http://www.ncbi.nlm.nih.gov/pubmed/28843943">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5637 href="http://dx.doi.org/10.1016/j.ajic.2017.06.017">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726580583"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5646 class=n-a></a>Martin EM, Russell D, Rubin Z, <i> et al.</i>: Elimination of Routine Contact Precautions for Endemic Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i>: A Retrospective Quasi-Experimental Study. <i>Infect Control Hosp Epidemiol.</i> 2016; <b>37</b>(11): 1323–30. <a target=xrefwindow id=d21151e5664 href="http://www.ncbi.nlm.nih.gov/pubmed/27457254">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5667 href="http://dx.doi.org/10.1017/ice.2016.156">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726580583">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d21151e5680 class=n-a></a>Morgan DJ, Wenzel RP, Bearman G: Contact Precautions for Endemic MRSA and VRE: Time to Retire Legal Mandates. <i>JAMA.</i> 2017; <b>318</b>(4): 329–30. <a target=xrefwindow id=d21151e5688 href="http://www.ncbi.nlm.nih.gov/pubmed/28654976">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5691 href="http://dx.doi.org/10.1001/jama.2017.7419">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726068306"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e5700 class=n-a></a>Almyroudis NG, Osawa R, Samonis G, <i> et al.</i>: Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-Resistant <i>Enterococcus</i> (VRE) and Its Impact on the Incidence of VRE <i>faecium</i> Bacteremia in Patients with Hematologic Malignancies. <i>Infect Control Hosp Epidemiol.</i> 2016; <b>37</b>(4): 398–403. <a target=xrefwindow id=d21151e5718 href="http://www.ncbi.nlm.nih.gov/pubmed/26750087">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5721 href="http://dx.doi.org/10.1017/ice.2015.310">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726068306">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d21151e5734 class=n-a></a>Donnelly JP, Maschmeyer G, Daenen S: Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. <i>Eur J Cancer.</i> 1992; <b>28A</b>(4–5): 873–8. <a target=xrefwindow id=d21151e5742 href="http://www.ncbi.nlm.nih.gov/pubmed/1524913">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5745 href="http://dx.doi.org/10.1016/0959-8049(92)90138-R">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d21151e5755 class=n-a></a>Cheng VC, Chen JH, Tai JW, <i> et al.</i>: Decolonization of gastrointestinal carriage of vancomycin-resistant <i>Enterococcus faecium</i>: case series and review of literature. <i>BMC Infect Dis.</i> 2014; <b>14</b>: 514. <a target=xrefwindow id=d21151e5769 href="http://www.ncbi.nlm.nih.gov/pubmed/25248287">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5773 href="http://dx.doi.org/10.1186/1471-2334-14-514">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5776 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4180964">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d21151e5785 class=n-a></a>Wong MT, Kauffman CA, Standiford HC, <i> et al.</i>: Effective suppression of vancomycin-resistant <i>Enterococcus</i> species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. <i>Clin Infect Dis.</i> 2001; <b>33</b>(9): 1476–82. <a target=xrefwindow id=d21151e5799 href="http://www.ncbi.nlm.nih.gov/pubmed/11588692">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5803 href="http://dx.doi.org/10.1086/322687">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d21151e5812 class=n-a></a>Montecalvo MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. <i>J Antimicrob Chemother.</i> 2003; <b>51</b>(Suppl 3): iii31–5. <a target=xrefwindow id=d21151e5820 href="http://www.ncbi.nlm.nih.gov/pubmed/12801940">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5823 href="http://dx.doi.org/10.1093/jac/dkg274">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d21151e5832 class=n-a></a>Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant <i>Enterococcus faecium</i>. <i>N Engl J Med.</i> 2002; <b>346</b>(11): 867–9. <a target=xrefwindow id=d21151e5843 href="http://www.ncbi.nlm.nih.gov/pubmed/11893808">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5846 href="http://dx.doi.org/10.1056/NEJM200203143461121">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d21151e5855 class=n-a></a>Scheetz MH, Knechtel SA, Malczynski M, <i> et al.</i>: Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant <i>Enterococcus faecium</i> strains parallels increasing linezolid consumption. <i>Antimicrob Agents Chemother.</i> 2008; <b>52</b>(6): 2256–9. <a target=xrefwindow id=d21151e5869 href="http://www.ncbi.nlm.nih.gov/pubmed/18391028">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5873 href="http://dx.doi.org/10.1128/AAC.00070-08">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2415807">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d21151e5885 class=n-a></a>McKinnell JA, Kunz DF, Chamot E, <i> et al.</i>: Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. <i>Infect Control Hosp Epidemiol.</i> 2012; <b>33</b>(7): 718–24. <a target=xrefwindow id=d21151e5896 href="http://www.ncbi.nlm.nih.gov/pubmed/22669234">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5899 href="http://dx.doi.org/10.1086/666331">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3879097">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d21151e5913 class=n-a></a>Tverdek FP, Rolston KV, Chemaly RF: Antimicrobial stewardship in patients with cancer. <i>Pharmacotherapy.</i> 2012; <b>32</b>(8): 722–34. <a target=xrefwindow id=d21151e5921 href="http://www.ncbi.nlm.nih.gov/pubmed/23307520">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5924 href="http://dx.doi.org/10.1002/j.1875-9114.2012.01162.x">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d21151e5933 class=n-a></a>Abbo LM, Ariza-Heredia EJ: Antimicrobial stewardship in immunocompromised hosts. <i>Infect Dis Clin North Am.</i> 2014; <b>28</b>(2): 263–79. <a target=xrefwindow id=d21151e5941 href="http://www.ncbi.nlm.nih.gov/pubmed/24857392">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5944 href="http://dx.doi.org/10.1016/j.idc.2014.01.008">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d21151e5953 class=n-a></a>Pultz NJ, Stiefel U, Donskey CJ: Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> in mice. <i>Antimicrob Agents Chemother.</i> 2005; <b>49</b>(8): 3513–6. <a target=xrefwindow id=d21151e5964 href="http://www.ncbi.nlm.nih.gov/pubmed/16048971">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5967 href="http://dx.doi.org/10.1128/AAC.49.8.3513-3516.2005">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1196280">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d21151e5980 class=n-a></a>Harbarth S, Cosgrove S, Carmeli Y: Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. <i>Antimicrob Agents Chemother.</i> 2002; <b>46</b>(6): 1619–28. <a target=xrefwindow id=d21151e5988 href="http://www.ncbi.nlm.nih.gov/pubmed/12019066">PubMed Abstract </a> | <a target=xrefwindow id=d21151e5991 href="http://dx.doi.org/10.1128/AAC.46.6.1619-1628.2002 ">Publisher Full Text </a> | <a target=xrefwindow id=d21151e5994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/127216">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d21151e6003 class=n-a></a>Carmeli Y, Samore MH, Huskins C: The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. <i>Arch Intern Med.</i> 1999; <b>159</b>(20): 2461–8. <a target=xrefwindow id=d21151e6011 href="http://www.ncbi.nlm.nih.gov/pubmed/10665895">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6014 href="http://dx.doi.org/10.1001/archinte.159.20.2461">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d21151e6023 class=n-a></a>de Bruin MA, Riley LW: Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic review. <i>BMC Infect Dis.</i> 2007; <b>7</b>: 24. <a target=xrefwindow id=d21151e6031 href="http://www.ncbi.nlm.nih.gov/pubmed/17425800">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6034 href="http://dx.doi.org/10.1186/1471-2334-7-24">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6037 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1863420">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d21151e6047 class=n-a></a>Freifeld AG, Bow EJ, Sepkowitz KA, <i> et al.</i>: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. <i>Clin Infect Dis.</i> 2011; <b>52</b>(4): e56–93. <a target=xrefwindow id=d21151e6058 href="http://www.ncbi.nlm.nih.gov/pubmed/21258094">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6061 href="http://dx.doi.org/10.1093/cid/cir073">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d21151e6070 class=n-a></a>Herc ES, Kauffman CA, Marini BL, <i> et al.</i>: Daptomycin nonsusceptible vancomycin resistant <i>Enterococcus</i> bloodstream infections in patients with hematological malignancies: risk factors and outcomes. <i>Leuk Lymphoma.</i> 2017; <b>58</b>(12): 2852–8. <a target=xrefwindow id=d21151e6084 href="http://www.ncbi.nlm.nih.gov/pubmed/28402152">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6088 href="http://dx.doi.org/10.1080/10428194.2017.1312665">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726976825"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6097 class=n-a></a>DiPippo AJ, Tverdek FP, Tarrand JJ, <i> et al.</i>: Daptomycin non-susceptible <i>Enterococcus faecium</i> in leukemia patients: Role of prior daptomycin exposure. <i>J Infect.</i> 2017; <b>74</b>(3): 243–7. <a target=xrefwindow id=d21151e6111 href="http://www.ncbi.nlm.nih.gov/pubmed/27845153">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6115 href="http://dx.doi.org/10.1016/j.jinf.2016.11.004">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6118 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5324836">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726976825">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726664987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6131 class=n-a></a>Sinel C, Jaussaud C, Auzou M, <i> et al.</i>: Mutant prevention concentrations of daptomycin for <i>Enterococcus faecium</i> clinical isolates. <i>Int J Antimicrob Agents.</i> 2016; <b>48</b>(4): 449–52. <a target=xrefwindow id=d21151e6145 href="http://www.ncbi.nlm.nih.gov/pubmed/27546218">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6149 href="http://dx.doi.org/10.1016/j.ijantimicag.2016.07.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726664987">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d21151e6162 class=n-a></a>Munita JM, Mishra NN, Alvarez D, <i> et al.</i>: Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible <i>Enterococcus faecium</i> harboring LiaSR substitutions. <i>Clin Infect Dis.</i> 2014; <b>59</b>(9): 1277–80. <a target=xrefwindow id=d21151e6176 href="http://www.ncbi.nlm.nih.gov/pubmed/25107294">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6180 href="http://dx.doi.org/10.1093/cid/ciu642">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6183 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4271039">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d21151e6192 class=n-a></a>Hall AD, Steed ME, Arias CA, <i> et al.</i>: Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant <i>Enterococcus</i> isolates in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrob Agents Chemother.</i> 2012; <b>56</b>(6): 3174–80. <a target=xrefwindow id=d21151e6210 href="http://www.ncbi.nlm.nih.gov/pubmed/22470111">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6213 href="http://dx.doi.org/10.1128/AAC.06439-11">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3370794">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726591136"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6226 class=n-a></a>Chuang YC, Lin HY, Chen PY, <i> et al.</i>: Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. <i>Clin Microbiol Infect.</i> 2016; <b>22</b>(10): 890.e1–890.e7. <a target=xrefwindow id=d21151e6237 href="http://www.ncbi.nlm.nih.gov/pubmed/27475738">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6240 href="http://dx.doi.org/10.1016/j.cmi.2016.07.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726591136">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727142892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6253 class=n-a></a>Britt NS, Potter EM, Patel N, <i> et al.</i>: Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. <i>Clin Infect Dis.</i> 2017; <b>64</b>(5): 605–13. <a target=xrefwindow id=d21151e6264 href="http://www.ncbi.nlm.nih.gov/pubmed/28011602">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6267 href="http://dx.doi.org/10.1093/cid/ciw815">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727142892">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726265724"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6280 class=n-a></a>Shukla BS, Shelburne S, Reyes K, <i> et al.</i>: Influence of Minimum Inhibitory Concentration in Clinical Outcomes of <i>Enterococcus faecium</i> Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint? <i>Clin Infect Dis.</i> 2016; <b>62</b>(12): 1514–20. <a target=xrefwindow id=d21151e6294 href="http://www.ncbi.nlm.nih.gov/pubmed/27045126">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6298 href="http://dx.doi.org/10.1093/cid/ciw173">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6301 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4885651">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726265724">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726891128"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6314 class=n-a></a>Chong PP, van Duin D, Bangdiwala A, <i> et al.</i>: Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L. <i>Clin Ther.</i> 2016; <b>38</b>(11): 2468–76. <a target=xrefwindow id=d21151e6325 href="http://www.ncbi.nlm.nih.gov/pubmed/27771176">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6328 href="http://dx.doi.org/10.1016/j.clinthera.2016.09.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726891128">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d21151e6341 class=n-a></a>Nemeth J, Oesch G, Kuster SP: Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. <i>J Antimicrob Chemother.</i> 2015; <b>70</b>(2): 382–95. <a target=xrefwindow id=d21151e6349 href="http://www.ncbi.nlm.nih.gov/pubmed/25266070">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6352 href="http://dx.doi.org/10.1093/jac/dku379">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d21151e6361 class=n-a></a>Kraft S, Mackler E, Schlickman P, <i> et al.</i>: Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. <i>Support Care Cancer.</i> 2011; <b>19</b>(12): 1969–74. <a target=xrefwindow id=d21151e6372 href="http://www.ncbi.nlm.nih.gov/pubmed/21110047">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6375 href="http://dx.doi.org/10.1007/s00520-010-1038-z">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726770550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6385 class=n-a></a>Nedved AN, DeFrates SR, Hladnik LM, <i> et al.</i>: Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy. <i>Pharmacotherapy.</i> 2016; <b>36</b>(10): 1087–94. <a target=xrefwindow id=d21151e6396 href="http://www.ncbi.nlm.nih.gov/pubmed/27521990">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6399 href="http://dx.doi.org/10.1002/phar.1824">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726770550">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6412 class=n-a></a>Jaksic B, Martinelli G, Perez-Oteyza J, <i> et al.</i>: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. <i>Clin Infect Dis.</i> 2006; <b>42</b>(5): 597–607. <a target=xrefwindow id=d21151e6423 href="http://www.ncbi.nlm.nih.gov/pubmed/16447103">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6426 href="http://dx.doi.org/10.1086/500139">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9164">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d21151e6439 class=n-a></a>Cohen N, Mihu CN, Seo SK, <i> et al.</i>: Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. <i>Biol Blood Marrow Transplant.</i> 2009; <b>15</b>(10): 1337–41. <a target=xrefwindow id=d21151e6450 href="http://www.ncbi.nlm.nih.gov/pubmed/19747643">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6453 href="http://dx.doi.org/10.1016/j.bbmt.2009.05.021">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728310499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6462 class=n-a></a>Lisboa LF, Miranda BG, Vieira MB, <i> et al.</i>: Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant <i>Enterococcus spp</i>. <i>Int J Infect Dis.</i> 2015; <b>33</b>: 171–6. <a target=xrefwindow id=d21151e6476 href="http://www.ncbi.nlm.nih.gov/pubmed/25660090">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6480 href="http://dx.doi.org/10.1016/j.ijid.2015.02.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728310499">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d21151e6493 class=n-a></a>Bi R, Qin T, Fan W, <i> et al.</i>: The Emerging Problem of Linezolid-resistant <i>Enterococcus</i>. <i>J Glob Antimicrob Resist.</i> 2017; pii: S2213-7165(17)30205-9. <a target=xrefwindow id=d21151e6504 href="http://www.ncbi.nlm.nih.gov/pubmed/29101082">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6507 href="http://dx.doi.org/10.1016/j.jgar.2017.10.018">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725551495"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6516 class=n-a></a>Britt NS, Potter EM, Patel N, <i> et al.</i>: Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. <i>Clin Infect Dis.</i> 2015; <b>61</b>(6): 871–8. <a target=xrefwindow id=d21151e6527 href="http://www.ncbi.nlm.nih.gov/pubmed/26063715">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6530 href="http://dx.doi.org/10.1093/cid/civ444">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4551009">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725551495">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727378073"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6548 class=n-a></a>Britt NS, Potter EM, Patel N, <i> et al.</i>: Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant <i>Enterococcus faecium</i> Bacteremia. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(5): pii: e02216-16. <a target=xrefwindow id=d21151e6562 href="http://www.ncbi.nlm.nih.gov/pubmed/28264856">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6566 href="http://dx.doi.org/10.1128/AAC.02216-16">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6569 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5404546">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727378073">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726591552"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6582 class=n-a></a>Zhao M, Liang L, Ji L, <i> et al.</i>: Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. <i>Int J Antimicrob Agents.</i> 2016; <b>48</b>(3): 231–8. <a target=xrefwindow id=d21151e6593 href="http://www.ncbi.nlm.nih.gov/pubmed/27475877">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6596 href="http://dx.doi.org/10.1016/j.ijantimicag.2016.06.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726591552">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d21151e6609 class=n-a></a>Chuang YC, Wang JT, Lin HY, <i> et al.</i>: Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. <i>BMC Infect Dis.</i> 2014; <b>14</b>: 687. <a target=xrefwindow id=d21151e6620 href="http://www.ncbi.nlm.nih.gov/pubmed/25495779">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6623 href="http://dx.doi.org/10.1186/s12879-014-0687-9">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4269951">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d21151e6636 class=n-a></a>Patel K, Kabir R, Ahmad S, <i> et al.</i>: Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus. <i>J Oncol Pharm Pract.</i> 2016; <b>22</b>(2): 212–218. <a target=xrefwindow id=d21151e6647 href="http://www.ncbi.nlm.nih.gov/pubmed/25326010">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6650 href="http://dx.doi.org/10.1177/1078155214556523">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d21151e6659 class=n-a></a>Klastersky J, de Naurois J, Rolston K, <i> et al.</i>: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. <i>Ann Oncol.</i> 2016; <b>27</b>(suppl 5): v111–v118. <a target=xrefwindow id=d21151e6670 href="http://www.ncbi.nlm.nih.gov/pubmed/27664247">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6673 href="http://dx.doi.org/10.1093/annonc/mdw325">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d21151e6682 class=n-a></a>Schaadt R, Sweeney D, Shinabarger D, <i> et al.</i>: <i>In vitro</i> activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. <i>Antimicrob Agents Chemother.</i> 2009; <b>53</b>(8): 3236–9. <a target=xrefwindow id=d21151e6696 href="http://www.ncbi.nlm.nih.gov/pubmed/19528279">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6700 href="http://dx.doi.org/10.1128/AAC.00228-09">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6703 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2715649">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d21151e6713 class=n-a></a>Livermore DM, Mushtaq S, Warner M, <i> et al.</i>: Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. <i>J Antimicrob Chemother.</i> 2009; <b>63</b>(4): 713–5. <a target=xrefwindow id=d21151e6724 href="http://www.ncbi.nlm.nih.gov/pubmed/19164418">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6727 href="http://dx.doi.org/10.1093/jac/dkp002">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d21151e6736 class=n-a></a>Rodríguez-Avial I, Culebras E, Betriu C, <i> et al.</i>: <i>In vitro</i> activity of tedizolid (TR-700) against linezolid-resistant staphylococci. <i>J Antimicrob Chemother.</i> 2012; <b>67</b>(1): 167–9. <a target=xrefwindow id=d21151e6750 href="http://www.ncbi.nlm.nih.gov/pubmed/21954458">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6754 href="http://dx.doi.org/10.1093/jac/dkr403">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d21151e6763 class=n-a></a>Brown SD, Traczewski MM: Comparative <i>In vitro</i> antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. <i>Antimicrob Agents Chemother.</i> 2010; <b>54</b>(5): 2063–9. <a target=xrefwindow id=d21151e6774 href="http://www.ncbi.nlm.nih.gov/pubmed/20231392">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6777 href="http://dx.doi.org/10.1128/AAC.01569-09">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6781 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2863606">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d21151e6790 class=n-a></a>Zurenko G, Bien P, Bensaci M, <i> et al.</i>: Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. <i>Ann Clin Microbiol Antimicrob.</i> 2014; <b>13</b>: 46. <a target=xrefwindow id=d21151e6801 href="http://www.ncbi.nlm.nih.gov/pubmed/25238753">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6804 href="http://dx.doi.org/10.1186/s12941-014-0046-0">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6808 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4291835">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d21151e6817 class=n-a></a>Flanagan S, Minassian SL, Morris D, <i> et al.</i>: Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(11): 6471–6. <a target=xrefwindow id=d21151e6828 href="http://www.ncbi.nlm.nih.gov/pubmed/25136024">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6831 href="http://dx.doi.org/10.1128/AAC.03431-14">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6835 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4249404">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717985358"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6844 class=n-a></a>Prokocimer P, De Anda C, Fang E, <i> et al.</i>: Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. <i>JAMA.</i> 2013; <b>309</b>(6): 559–69. <a target=xrefwindow id=d21151e6855 href="http://www.ncbi.nlm.nih.gov/pubmed/23403680">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6858 href="http://dx.doi.org/10.1001/jama.2013.241">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717985358">F1000 Recommendation</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d21151e6872 class=n-a></a>Moran GJ, Fang E, Corey GR, <i> et al.</i>: Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infect Dis.</i> 2014; <b>14</b>(8): 696–705. <a target=xrefwindow id=d21151e6883 href="http://www.ncbi.nlm.nih.gov/pubmed/24909499">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6886 href="http://dx.doi.org/10.1016/S1473-3099(14)70737-6">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d21151e6895 class=n-a></a>De Vriese AS, Coster RV, Smet J, <i> et al.</i>: Linezolid-induced inhibition of mitochondrial protein synthesis. <i>Clin Infect Dis.</i> 2006; <b>42</b>(8): 1111–7. <a target=xrefwindow id=d21151e6906 href="http://www.ncbi.nlm.nih.gov/pubmed/16575728">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6909 href="http://dx.doi.org/10.1086/501356">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d21151e6918 class=n-a></a>Flanagan S, McKee EE, Das D, <i> et al.</i>: Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(1): 178–85. <a target=xrefwindow id=d21151e6929 href="http://www.ncbi.nlm.nih.gov/pubmed/25331703">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6932 href="http://dx.doi.org/10.1128/AAC.03684-14">Publisher Full Text </a> | <a target=xrefwindow id=d21151e6936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4291347">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726433217"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e6945 class=n-a></a>Lodise TP, Bidell MR, Flanagan SD, <i> et al.</i>: Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. <i>J Antimicrob Chemother.</i> 2016; <b>71</b>(9): 2553–8. <a target=xrefwindow id=d21151e6956 href="http://www.ncbi.nlm.nih.gov/pubmed/27317442">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6959 href="http://dx.doi.org/10.1093/jac/dkw206">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726433217">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d21151e6972 class=n-a></a>Patel R, Gallagher JC: Vancomycin-resistant enterococcal bacteremia pharmacotherapy. <i>Ann Pharmacother.</i> 2015; <b>49</b>(1): 69–85. <a target=xrefwindow id=d21151e6980 href="http://www.ncbi.nlm.nih.gov/pubmed/25352037">PubMed Abstract </a> | <a target=xrefwindow id=d21151e6983 href="http://dx.doi.org/10.1177/1060028014556879">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d21151e6992 class=n-a></a>Putnam SD, Sader HS, Moet GJ, <i> et al.</i>: Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. <i>Diagn Microbiol Infect Dis.</i> 2010; <b>67</b>(4): 359–68. <a target=xrefwindow id=d21151e7003 href="http://www.ncbi.nlm.nih.gov/pubmed/20638605">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7006 href="http://dx.doi.org/10.1016/j.diagmicrobio.2010.03.009">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d21151e7016 class=n-a></a>Draghi DC, Benton BM, Krause KM, <i> et al.</i>: <i>In vitro</i> activity of telavancin against recent Gram-positive clinical isolates: results of the 2004–05 Prospective European Surveillance Initiative. <i>J Antimicrob Chemother.</i> 2008; <b>62</b>(1): 116–21. <a target=xrefwindow id=d21151e7030 href="http://www.ncbi.nlm.nih.gov/pubmed/18424792">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7034 href="http://dx.doi.org/10.1093/jac/dkn124">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d21151e7043 class=n-a></a>Krause KM, Renelli M, Difuntorum S, <i> et al.</i>: <i>In vitro</i> activity of telavancin against resistant gram-positive bacteria. <i>Antimicrob Agents Chemother.</i> 2008; <b>52</b>(7): 2647–52. <a target=xrefwindow id=d21151e7057 href="http://www.ncbi.nlm.nih.gov/pubmed/18443122">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7061 href="http://dx.doi.org/10.1128/AAC.01398-07">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2443888">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d21151e7073 class=n-a></a>Stryjewski ME, Graham DR, Wilson SE, <i> et al.</i>: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. <i>Clin Infect Dis.</i> 2008; <b>46</b>(11): 1683–93. <a target=xrefwindow id=d21151e7084 href="http://www.ncbi.nlm.nih.gov/pubmed/18444791">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7087 href="http://dx.doi.org/10.1086/587896">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d21151e7096 class=n-a></a>Rubinstein E, Lalani T, Corey GR, <i> et al.</i>: Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. <i>Clin Infect Dis.</i> 2011; <b>52</b>(1): 31–40. <a target=xrefwindow id=d21151e7107 href="http://www.ncbi.nlm.nih.gov/pubmed/21148517">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7110 href="http://dx.doi.org/10.1093/cid/ciq031">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7114 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3060890">Free Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d21151e7123 class=n-a></a>Barber KE, King ST, Stover KR, <i> et al.</i>: Therapeutic options for vancomycin-resistant enterococcal bacteremia. <i>Expert Rev Anti Infect Ther.</i> 2015; <b>13</b>(3): 363–77. <a target=xrefwindow id=d21151e7134 href="http://www.ncbi.nlm.nih.gov/pubmed/25661903">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7137 href="http://dx.doi.org/10.1586/14787210.2015.1001839">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d21151e7146 class=n-a></a>Biedenbach DJ, Bell JM, Sader HS, <i> et al.</i>: Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. <i>Antimicrob Agents Chemother.</i> 2009; <b>53</b>(3): 1260–3. <a target=xrefwindow id=d21151e7157 href="http://www.ncbi.nlm.nih.gov/pubmed/19124664">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7160 href="http://dx.doi.org/10.1128/AAC.01453-08">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7164 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2650578">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d21151e7174 class=n-a></a>Jones RN, Sader HS, Flamm RK: Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). <i>Diagn Microbiol Infect Dis.</i> 2013; <b>75</b>(3): 304–7. <a target=xrefwindow id=d21151e7182 href="http://www.ncbi.nlm.nih.gov/pubmed/23357293">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7185 href="http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.024">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d21151e7194 class=n-a></a>Boucher HW, Wilcox M, Talbot GH, <i> et al.</i>: Once-weekly dalbavancin versus daily conventional therapy for skin infection. <i>N Engl J Med.</i> 2014; <b>370</b>(23): 2169–79. <a target=xrefwindow id=d21151e7205 href="http://www.ncbi.nlm.nih.gov/pubmed/24897082">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7208 href="http://dx.doi.org/10.1056/NEJMoa1310480">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d21151e7217 class=n-a></a>Seltzer E, Dorr MB, Goldstein BP, <i> et al.</i>: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. <i>Clin Infect Dis.</i> 2003; <b>37</b>(10): 1298–303. <a target=xrefwindow id=d21151e7228 href="http://www.ncbi.nlm.nih.gov/pubmed/14583862">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7231 href="http://dx.doi.org/10.1086/379015">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e7240 class=n-a></a>Jauregui LE, Babazadeh S, Seltzer E, <i> et al.</i>: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. <i>Clin Infect Dis.</i> 2005; <b>41</b>(10): 1407–15. <a target=xrefwindow id=d21151e7251 href="http://www.ncbi.nlm.nih.gov/pubmed/16231250">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7254 href="http://dx.doi.org/10.1086/497271">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1169">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d21151e7267 class=n-a></a>Raad I, Darouiche R, Vazquez J, <i> et al.</i>: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. <i>Clin Infect Dis.</i> 2005; <b>40</b>(3): 374–80. <a target=xrefwindow id=d21151e7278 href="http://www.ncbi.nlm.nih.gov/pubmed/15668859">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7281 href="http://dx.doi.org/10.1086/427283">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d21151e7290 class=n-a></a>Allen NE, Nicas TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. <i>FEMS Microbiol Rev.</i> 2003; <b>26</b>(5): 511–32. <a target=xrefwindow id=d21151e7298 href="http://www.ncbi.nlm.nih.gov/pubmed/12586393">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7301 href="http://dx.doi.org/10.1111/j.1574-6976.2003.tb00628.x">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d21151e7311 class=n-a></a>Cooper RD, Snyder NJ, Zweifel MJ, <i> et al.</i>: Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. <i>J Antibiot (Tokyo).</i> 1996; <b>49</b>(6): 575–81. <a target=xrefwindow id=d21151e7322 href="http://www.ncbi.nlm.nih.gov/pubmed/8698642">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7325 href="http://dx.doi.org/10.7164/antibiotics.49.575">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d21151e7334 class=n-a></a>Morrissey I, Seifert H, Canton R, <i> et al.</i>: Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. <i>J Antimicrob Chemother.</i> 2013; <b>68</b>(1): 164–7. <a target=xrefwindow id=d21151e7345 href="http://www.ncbi.nlm.nih.gov/pubmed/22941898">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7348 href="http://dx.doi.org/10.1093/jac/dks344">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d21151e7357 class=n-a></a>Baltch AL, Smith RP, Ritz WJ, <i> et al.</i>: Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant <i>Enterococcus faecium</i>. <i>Antimicrob Agents Chemother.</i> 1998; <b>42</b>(10): 2564–8. <a target=xrefwindow id=d21151e7371 href="http://www.ncbi.nlm.nih.gov/pubmed/9756756">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7375 href="http://www.ncbi.nlm.nih.gov/pmc/articles/105897">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727965218"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e7384 class=n-a></a>Belley A, Lalonde-Séguin D, Arhin FF, <i> et al.</i>: Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant <i>Enterococcus faecium</i> Isolates in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model of Infection. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(10): pii: e01265-17. <a target=xrefwindow id=d21151e7402 href="http://www.ncbi.nlm.nih.gov/pubmed/28784674">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7405 href="http://dx.doi.org/10.1128/AAC.01265-17">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7408 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5610485">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727965218">F1000 Recommendation</a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d21151e7421 class=n-a></a>Meagher AK, Ambrose PG, Grasela TH, <i> et al.</i>: Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. <i>Diagn Microbiol Infect Dis.</i> 2005; <b>52</b>(3): 165–71. <a target=xrefwindow id=d21151e7432 href="http://www.ncbi.nlm.nih.gov/pubmed/16105560">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7435 href="http://dx.doi.org/10.1016/j.diagmicrobio.2005.05.006">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d21151e7444 class=n-a></a>Renteria MI, Biedenbach DJ, Bouchillon SK, <i> et al.</i>: <i>In vitro</i> activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007–2012. <i>Diagn Microbiol Infect Dis.</i> 2014; <b>79</b>(1): 54–9. <a target=xrefwindow id=d21151e7458 href="http://www.ncbi.nlm.nih.gov/pubmed/24582580">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7462 href="http://dx.doi.org/10.1016/j.diagmicrobio.2014.01.017">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d21151e7472 class=n-a></a>European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee: EUCAST technical note on tigecycline. <i>Clin Microbiol Infect.</i> 2006; <b>12</b>(11): 1147–9. <a target=xrefwindow id=d21151e7480 href="http://www.ncbi.nlm.nih.gov/pubmed/17063597">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7483 href="http://dx.doi.org/10.1111/j.1469-0691.2006.01578.x">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d21151e7492 class=n-a></a>Insert TP, Philadelphia PA, Wyeth Pharmaceuticals Inc: Organism (no tested)/% susceptible/antimicrobial agent MIC50 MIC90 Range resistant a. 2005. </span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d21151e7501 class=n-a></a>Sader HS, Jones RN, Stilwell MG, <i> et al.</i>: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. <i>Diagn Microbiol Infect Dis.</i> 2005; <b>52</b>(3): 181–6. <a target=xrefwindow id=d21151e7512 href="http://www.ncbi.nlm.nih.gov/pubmed/16105562">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7515 href="http://dx.doi.org/10.1016/j.diagmicrobio.2005.05.005">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d21151e7524 class=n-a></a>Noskin GA: Tigecycline: a new glycylcycline for treatment of serious infections. <i>Clin Infect Dis.</i> 2005; <b>41 Suppl 5</b>: S303–14. <a target=xrefwindow id=d21151e7532 href="http://www.ncbi.nlm.nih.gov/pubmed/16080069">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7535 href="http://dx.doi.org/10.1086/431672">Publisher Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d21151e7544 class=n-a></a>Ellis-Grosse EJ, Babinchak T, Dartois N, <i> et al.</i>: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. <i>Clin Infect Dis.</i> 2005; <b>41 Suppl 5</b>: S341–53. <a target=xrefwindow id=d21151e7555 href="http://www.ncbi.nlm.nih.gov/pubmed/16080072">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7558 href="http://dx.doi.org/10.1086/431675">Publisher Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d21151e7567 class=n-a></a>Babinchak T, Ellis-Grosse E, Dartois N, <i> et al.</i>: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. <i>Clin Infect Dis.</i> 2005; <b>41 Suppl 5</b>: S354–67. <a target=xrefwindow id=d21151e7578 href="http://www.ncbi.nlm.nih.gov/pubmed/16080073">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7581 href="http://dx.doi.org/10.1086/431676">Publisher Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d21151e7591 class=n-a></a>Yim J, Smith JR, Rybak MJ: Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. <i>Pharmacotherapy.</i> 2017; <b>37</b>(5): 579–92. <a target=xrefwindow id=d21151e7599 href="http://www.ncbi.nlm.nih.gov/pubmed/28273381">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7602 href="http://dx.doi.org/10.1002/phar.1922">Publisher Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11589956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e7611 class=n-a></a>Dhand A, Bayer AS, Pogliano J, <i> et al.</i>: Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant <i>Staphylococcus aureus</i>: role of enhanced daptomycin binding. <i>Clin Infect Dis.</i> 2011; <b>53</b>(2): 158–63. <a target=xrefwindow id=d21151e7625 href="http://www.ncbi.nlm.nih.gov/pubmed/21690622">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7629 href="http://dx.doi.org/10.1093/cid/cir340">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3697476">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11589956">F1000 Recommendation</a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d21151e7645 class=n-a></a>Sakoulas G, Bayer AS, Pogliano J, <i> et al.</i>: Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant <i>Enterococcus faecium</i>. <i>Antimicrob Agents Chemother.</i> 2012; <b>56</b>(2): 838–44. <a target=xrefwindow id=d21151e7659 href="http://www.ncbi.nlm.nih.gov/pubmed/22123698">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7663 href="http://dx.doi.org/10.1128/AAC.05551-11">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3264218">Free Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d21151e7675 class=n-a></a>Sakoulas G, Rose W, Nonejuie P, <i> et al.</i>: Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant <i>Enterococcus faecium</i>. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(3): 1494–500. <a target=xrefwindow id=d21151e7689 href="http://www.ncbi.nlm.nih.gov/pubmed/24366742">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7693 href="http://dx.doi.org/10.1128/AAC.02274-13">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7696 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3957885">Free Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d21151e7705 class=n-a></a>Hall Snyder A, Werth BJ, Barber KE, <i> et al.</i>: Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an <i>in vitro</i> pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>J Antimicrob Chemother.</i> 2014; <b>69</b>(8): 2148–54. <a target=xrefwindow id=d21151e7719 href="http://www.ncbi.nlm.nih.gov/pubmed/24777900">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7723 href="http://dx.doi.org/10.1093/jac/dku113">Publisher Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d21151e7732 class=n-a></a>Werth BJ, Barber KE, Tran KN, <i> et al.</i>: Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. <i>J Antimicrob Chemother.</i> 2015; <b>70</b>(2): 489–93. <a target=xrefwindow id=d21151e7743 href="http://www.ncbi.nlm.nih.gov/pubmed/25304643">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7746 href="http://dx.doi.org/10.1093/jac/dku386">Publisher Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d21151e7756 class=n-a></a>Hindler JA, Wong-Beringer A, Charlton CL, <i> et al.</i>: <i>In vitro</i> activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(7): 4279–88. <a target=xrefwindow id=d21151e7770 href="http://www.ncbi.nlm.nih.gov/pubmed/25963982">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7774 href="http://dx.doi.org/10.1128/AAC.05077-14">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4468720">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725339727"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e7786 class=n-a></a>Smith JR, Barber KE, Raut A, <i> et al.</i>: β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i>. <i>J Antimicrob Chemother.</i> 2015; <b>70</b>(6): 1738–43. <a target=xrefwindow id=d21151e7804 href="http://www.ncbi.nlm.nih.gov/pubmed/25645208">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7807 href="http://dx.doi.org/10.1093/jac/dkv007">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7810 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4542582">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725339727">F1000 Recommendation</a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d21151e7823 class=n-a></a>Smith JR, Barber KE, Raut A, <i> et al.</i>: β-Lactams enhance daptomycin activity against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> in <i>in vitro</i> pharmacokinetic/pharmacodynamic models. <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(5): 2842–8. <a target=xrefwindow id=d21151e7844 href="http://www.ncbi.nlm.nih.gov/pubmed/25753639">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7847 href="http://dx.doi.org/10.1128/AAC.00053-15">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4394769">Free Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d21151e7859 class=n-a></a>Sierra-Hoffman M, Iznaola O, Goodwin M, <i> et al.</i>: Combination therapy with ampicillin and daptomycin for treatment of <i>Enterococcus faecalis</i> endocarditis. <i>Antimicrob Agents Chemother.</i> 2012; <b>56</b>(11): 6064. <a target=xrefwindow id=d21151e7873 href="http://www.ncbi.nlm.nih.gov/pubmed/22964255">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7877 href="http://dx.doi.org/10.1128/AAC.01760-12">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7880 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3486546">Free Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d21151e7889 class=n-a></a>Sakoulas G, Nonejuie P, Nizet V, <i> et al.</i>: Treatment of high-level gentamicin-resistant <i>Enterococcus faecalis</i> endocarditis with daptomycin plus ceftaroline. <i>Antimicrob Agents Chemother.</i> 2013; <b>57</b>(8): 4042–5. <a target=xrefwindow id=d21151e7903 href="http://www.ncbi.nlm.nih.gov/pubmed/23689728">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7907 href="http://dx.doi.org/10.1128/AAC.02481-12">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3719745">Free Full Text </a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d21151e7919 class=n-a></a>Piszczek J, Hutchinson J, Partlow E: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis-authors' response. <i>J Antimicrob Chemother.</i> 2015; <b>70</b>(4): 1273–4. <a target=xrefwindow id=d21151e7927 href="http://www.ncbi.nlm.nih.gov/pubmed/25558072">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7930 href="http://dx.doi.org/10.1093/jac/dku514">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d21151e7940 class=n-a></a>Rice LB, Eliopoulos GM, Moellering RC Jr: <i>In vitro</i> synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. <i>Antimicrob Agents Chemother.</i> 1989; <b>33</b>(4): 470–3. <a target=xrefwindow id=d21151e7951 href="http://www.ncbi.nlm.nih.gov/pubmed/2543282">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7954 href="http://dx.doi.org/10.1128/AAC.33.4.470">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/172462">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d21151e7967 class=n-a></a>Descourouez JL, Jorgenson MR, Wergin JE, <i> et al.</i>: Fosfomycin synergy <i>in vitro</i> with amoxicillin, daptomycin, and linezolid against vancomycin-resistant <i>Enterococcus faecium</i> from renal transplant patients with infected urinary stents. <i>Antimicrob Agents Chemother.</i> 2013; <b>57</b>(3): 1518–20. <a target=xrefwindow id=d21151e7985 href="http://www.ncbi.nlm.nih.gov/pubmed/23263002">PubMed Abstract </a> | <a target=xrefwindow id=d21151e7988 href="http://dx.doi.org/10.1128/AAC.02099-12">Publisher Full Text </a> | <a target=xrefwindow id=d21151e7991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3591908">Free Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726560085"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21151e8000 class=n-a></a>Hall Snyder AD, Werth BJ, Nonejuie P, <i> et al.</i>: Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrob Agents Chemother.</i> 2016; <b>60</b>(10): 5716–23. <a target=xrefwindow id=d21151e8014 href="http://www.ncbi.nlm.nih.gov/pubmed/27431211">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8018 href="http://dx.doi.org/10.1128/AAC.00687-16">Publisher Full Text </a> | <a target=xrefwindow id=d21151e8021 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5038233">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726560085">F1000 Recommendation</a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d21151e8034 class=n-a></a>Rice LB, Eliopoulos CT, Yao JD, <i> et al.</i>: <i>In vivo</i> activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. <i>Diagn Microbiol Infect Dis.</i> 1992; <b>15</b>(2): 173–6. <a target=xrefwindow id=d21151e8048 href="http://www.ncbi.nlm.nih.gov/pubmed/1315234">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8052 href="http://dx.doi.org/10.1016/0732-8893(92)90045-U">Publisher Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d21151e8061 class=n-a></a>Jenkins I: Linezolid- and vancomycin-resistant <i>Enterococcus faecium</i> endocarditis: successful treatment with tigecycline and daptomycin. <i>J Hosp Med.</i> 2007; <b>2</b>(5): 343–4. <a target=xrefwindow id=d21151e8072 href="http://www.ncbi.nlm.nih.gov/pubmed/17935250">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8075 href="http://dx.doi.org/10.1002/jhm.236">Publisher Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d21151e8084 class=n-a></a>Schutt AC, Bohm NM: Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. <i>Ann Pharmacother.</i> 2009; <b>43</b>(12): 2108–12. <a target=xrefwindow id=d21151e8092 href="http://www.ncbi.nlm.nih.gov/pubmed/19887592">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8095 href="http://dx.doi.org/10.1345/aph.1M324">Publisher Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d21151e8105 class=n-a></a>Jaspan HB, Brothers AW, Campbell AJ, <i> et al.</i>: Multidrug-resistant <i>Enterococcus faecium</i> meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. <i>Pediatr Infect Dis J.</i> 2010; <b>29</b>(4): 379–81. <a target=xrefwindow id=d21151e8119 href="http://www.ncbi.nlm.nih.gov/pubmed/20010311">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8123 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4778705">Free Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d21151e8132 class=n-a></a>Polidori M, Nuccorini A, Tascini C, <i> et al.</i>: Vancomycin-resistant <i>Enterococcus faecium</i> (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline. <i>J Chemother.</i> 2011; <b>23</b>(4): 240–1. <a target=xrefwindow id=d21151e8146 href="http://www.ncbi.nlm.nih.gov/pubmed/21803704">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8150 href="http://dx.doi.org/10.1179/joc.2011.23.4.240">Publisher Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a name=d21151e8159 class=n-a></a>Noskin GA, Siddiqui F, Stosor V, <i> et al.</i>: Successful treatment of persistent vancomycin-resistant <i>Enterococcus faecium</i> bacteremia with linezolid and gentamicin. <i>Clin Infect Dis.</i> 1999; <b>28</b>(3): 689–90. <a target=xrefwindow id=d21151e8173 href="http://www.ncbi.nlm.nih.gov/pubmed/10194104">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8177 href="http://dx.doi.org/10.1086/517221">Publisher Full Text </a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d21151e8186 class=n-a></a>Luther MK, Arvanitis M, Mylonakis E, <i> et al.</i>: Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming <i>Enterococcus faecalis</i> or E. faecium in an <i>in vitro</i> pharmacodynamic model using simulated endocardial vegetations and an <i>in vivo</i> survival assay using Galleria mellonella larvae. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(8): 4612–20. <a target=xrefwindow id=d21151e8207 href="http://www.ncbi.nlm.nih.gov/pubmed/24867993">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8210 href="http://dx.doi.org/10.1128/AAC.02790-13">Publisher Full Text </a> | <a target=xrefwindow id=d21151e8213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4136052">Free Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a name=d21151e8222 class=n-a></a>Allen GP, Cha R, Rybak MJ: <i>In vitro</i> activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an <i>in vitro</i> pharmacodynamic model. <i>Antimicrob Agents Chemother.</i> 2002; <b>46</b>(8): 2606–12. <a target=xrefwindow id=d21151e8236 href="http://www.ncbi.nlm.nih.gov/pubmed/12121940">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8240 href="http://dx.doi.org/10.1128/AAC.46.8.2606-2612.2002">Publisher Full Text </a> | <a target=xrefwindow id=d21151e8243 href="http://www.ncbi.nlm.nih.gov/pmc/articles/127363">Free Full Text </a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d21151e8252 class=n-a></a>Lewis JS 2nd, Owens A, Cadena J, <i> et al.</i>: Emergence of daptomycin resistance in <i>Enterococcus faecium</i> during daptomycin therapy. <i>Antimicrob Agents Chemother.</i> 2005; <b>49</b>(4): 1664–5. <a target=xrefwindow id=d21151e8266 href="http://www.ncbi.nlm.nih.gov/pubmed/15793168">PubMed Abstract </a> | <a target=xrefwindow id=d21151e8270 href="http://dx.doi.org/10.1128/AAC.49.4.1664-1665.2005">Publisher Full Text </a> | <a target=xrefwindow id=d21151e8273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1068653">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-3.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-3.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, USA<br/> <sup>2</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, USA<br/> <p> <div class=margin-bottom> Esther Benamu <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stanley Deresinski <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-3/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 02 Jan 2018, 7:3 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11831.1">https://doi.org/10.12688/f1000research.11831.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Benamu E and Deresinski S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12785 data-id=11831 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11831.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-3/v1/pdf?article_uuid=c195b19b-48a5-45e3-a687-89d291b6b2fd" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11831.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Benamu E and Deresinski S. Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):3 (<a href="https://doi.org/10.12688/f1000research.11831.1" target=_blank>https://doi.org/10.12688/f1000research.11831.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11831 id=mobile-track-article-signin-11831 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11831?target=/articles/7-3.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12785 /> <input name=articleId type=hidden value=11831 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Catherine Liu</strong>, Vaccine and Infectious Disease Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, USA; Division of Allergy and Infectious Disease, University of Washington, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Erica Stohs</strong>, Division of Allergy and Infectious Diseases, University of Washington, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Vincent Cattoir</strong>, Department of Clinical Microbiology, Rennes University Hospital, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jayanta Haldar</strong>, Chemical Biology and Medicinal Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre For Advanced Scientific Research, India </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-3.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-3.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29179-29179></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29178-29177></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29177-29178></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-3/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>02 Jan 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Catherine Liu</strong>, Vaccine and Infectious Disease Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, USA; Division of Allergy and Infectious Disease, University of Washington, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Erica Stohs</strong>, Division of Allergy and Infectious Diseases, University of Washington, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vincent Cattoir</strong>, Department of Clinical Microbiology, Rennes University Hospital, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jayanta Haldar</strong>, Chemical Biology and Medicinal Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre For Advanced Scientific Research, India </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-3.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-3/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Vancomycin-resistant enterococcus infection...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-3/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-3/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-3/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Benamu E and Deresinski S');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-3/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-3",
            templates : {
                twitter : "Vancomycin-resistant enterococcus infection in the hematopoietic.... Benamu E and Deresinski S, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-3/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11831/12785")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12785");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29177": 0,
                           "29178": 0,
                           "29179": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d468e5a0-7485-4af1-b7f1-b728e6113c9a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-3.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-3.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-3.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-3.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-3.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>